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Elise Deshommes1, Robert Tardif2, Marc Edwards3, Sébastien Sauvé4* and Michèle Prévost1Abstract
In vivo estimations of Pb particle bioavailability are costly and variable, because of the nature of animal assays. The
most feasible alternative for increasing the number of investigations carried out on Pb particle bioavailability is
in vitro testing. This testing method requires calibration using in vivo data on an adapted animal model, so that the
results will be valid for childhood exposure assessment. Also, the test results must be reproducible within and
between laboratories. The Relative Bioaccessibility Leaching Procedure, which is calibrated with in vivo data on soils,
presents the highest degree of validation and simplicity. This method could be applied to Pb particles, including
those in paint and dust, and those in drinking water systems, which although relevant, have been poorly
investigated up to now for childhood exposure assessment.
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Introduction
Lead [Pb] is hazardous to humans, and is of particular
concern for fetuses, infants, children, and women of child-
bearing age [1,2]. Knowledge of Pb toxicity has progressed
significantly since the 1970s. Initially considered toxic only
at blood lead levels [BLLs] over 60 μg/dL, it is now consid-
ered to have no definable threshold below which “no
harmful effect” can be determined [3]. Early studies de-
monstrate the immediate and long-term effects of low Pb
level exposure during childhood, such as neurobehavioral
and neurodevelopmental deficiencies, and effects on
growth, hearing, and blood pressure [3,4]. Pb uptake may
reduce the intelligence quotient [IQ] of infants and chil-
dren, and affect some brain responses, even at low BLLs.
Recently, the effect on IQ has been shown to be even stron-
ger at low BLLs, since decrements in IQ were more dra-
matic between BLLs categories < 5 μg/dL and 5–9.9 μg/dL
than between categories 5–9.9 μg/dL and ≥ 10 μg/dL,
which has led to a reconsideration of the 10 μg/dL health
advisory level [5-8]. Indeed, the European Food and Safety
Agency (EFSA) has set the 95th percentile lower confidence
limit of the benchmark dose [BMD] of an incremental 1%* Correspondence: sebastien.sauve@umontreal.ca
4Department of Chemistry, Université de Montréal, 2900, Édouard-Montpetit,
Montréal, QC H3C 3A7, Canada
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Creative Commons Attribution License (http:/
distribution, and reproduction in any mediumrisk (BMDL01) at 1.2 μg Pb/dL as a reference point when
assessing the risk of intellectual deficits in children mea-
sured by the Full Scale IQ score [9]. Also, the EU Risk As-
sessment Report states that Pb exposure effects cannot be
measured reliably at BLLs < 5 μg/dL, due to the limited
precision of methods of behavioral testing and Pb quantita-
tion in blood [10]. Considering the neurocognitive and
neurophysiological effects observed at low BLLs, a new
reference level of 5 μg/dL was recently set by the CDC, and
will be revised downwards every 4 years [11].
Early studies on the health impacts on children led to
public policies to remove Pb sources from food and
leaded gasoline, resulting in the steady decline of BLLs
in recent years [3,12-15]. Remedial actions have also
been taken to decrease Pb levels in the soil and dust of
Pb-contaminated sites, although decreasing these levels
may not always result in lower BLLs in children [14-17].
Lead paint is a common cause of clinical Pb poisoning,
and remains a strong contributor to childhood exposure,
as it is still present in houses built before 1978 in the
United States; its abatement cost is estimated in the
billions of dollars [3,14,15]. Now, as BLL guidelines be-
come more stringent, the relative contribution of tap
water to total Pb exposure may become highly signifi-
cant [18-21]. Lanphear et al. report that Pb occurrence
in water > 5 μg/L after 1 min of flushing increases the
BLLs of children aged 6–24 months by 1.02 μg/dL,Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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cently, abnormal BLLs in young children have been
associated with elevated Pb concentrations in drinking
water, particulate Pb representing a significant fraction
of this [23-26]. However, because of its sporadic occur-
rence, exposure to particulate Pb in drinking water is es-
pecially difficult to characterize [27]. Most regulatory
and research efforts have assumed that soluble Pb is the
predominant form of exposure. Interest in particulate Pb
is now growing, because of its potential contribution to
chronic and acute exposure [27-29]. The most direct ap-
proach to assessing the contribution of various Pb sources
to human exposure is to conduct epidemiological studies
or in vivo studies. Numerous epidemiological studies of
particulate Pb exposure from various media (i.e. air, soil,
paint, and dust) have been reviewed [14,15,30,31]. Some of
these revealed a significant relationship between environ-
mental Pb levels and BLLs, and a decrease in BLLs after
remediating Pb sources, providing direct measurements of
exposure and its impacts on body burden. However, they
are challenging to carry out because of cost, the variability
of exposure among the population studied, and BLL evo-
lution since exposure [32].
In vivo experiments are much simpler to plan and per-
form than epidemiological studies. Key parameters can
be controlled, such as exposure levels and conditions,
and the relationships between exposure levels and levels
of Pb absorbed by the in vivo specimen tested can be
quantified. However, the measurements are indirect, based
on animal models, and require extrapolation to human ex-
posure conditions. A primary outcome of in vivo studies of
oral Pb exposure is the oral bioavailability of Pb occurring
in both dissolved and particulate form. Several in vivo
experiments have been performed, first with readily soluble
Pb forms such as Pb acetate [PbAc], and then mostly with
Pb-contaminated soils. But comprehensive bioavailability
experiments are long, expensive, demanding, and the use of
animal models can raise ethical issues. Moreover, bioavail-
ability results show significant variability, which is inherent
to the use of animal models.
In vitro experiments are simpler, faster, cheaper, and
highly reproducible, and do not raise ethical concerns,
and therefore are best suited to test replication. How-
ever, they can only assess the bioaccessibility of Pb,
defined as the fraction of ingested Pb dissolved during
the digestion process and available for absorption into
the systemic circulation (bloodstream). Bioavailability is
the fraction actually available and taken up by an organ-
ism, while bioaccessibility is an experimentally deter-
mined estimate of what is potentially bioavailable [33]. If
well calibrated, an in vitro test can adequately predict
in vivo results. A significant number of bioaccessibility
studies have been conducted on Pb contaminated soils.
However, the bioaccessibility of other sources of Pbparticles to which infants/children can be exposed
(paint, dust, drinking water particles, toys, and food) has
not been thoroughly investigated. In vivo testing of these
particulate forms can be limited by experimental con-
straints, which can be addressed using in vitro tests.
This review summarizes the information available on
the bioavailability and bioaccessibility testing that have
been proposed for estimating the oral bioavailability of
Pb particles in children. Our objectives are to identify
the strengths and weaknesses of these procedures, to
highlight differences between them to support the inter-
pretation of study conclusions, and, finally, to draw
attention to gaps in the data on Pb particles that are
relevant for childhood exposure assessment.
Approaches to estimating Pb bioavailability
Many definitions of bioavailability have been proposed
for soil and sediments [33]. In this review, the term “oral
bioavailability” refers to the amount of ingested Pb that
reaches the systemic circulation and that is likely to ac-
cumulate in the body, including organs and bones. His-
torically, bioavailability has been determined in the
laboratory using in vivo testing. In vivo testing to esti-
mate Pb bioavailability must be carried out over an
extended period to ensure that the metal is absorbed,
retained, and excreted. The half-life of Pb is about 25
days in blood, 40 days in soft tissues, and 25 years in
bones [34]. Early human experiments were conducted
using Pb in the diet, Pb tracers, or Pb salts labeled with
radioactive Pb203 [35-37]. A detailed review and critical
evaluation of these studies is available in Mushak (1991)
[30]. Such studies helped identify absorption mechan-
isms for soluble Pb and interactions with food, although
there are still some uncertainties on the specific sites
where Pb uptake actually takes place [30]. However,
these results cannot be directly extrapolated to Pb parti-
cles in soil, dust, paint, or drinking water, because of po-
tential matrix effects. A more recent study measured the
bioavailability of soil borne Pb in human adults, and is the
only study performed on humans with Pb-contaminated
soil [38]. The target population was adults, whose digest-
ive absorption processes differ markedly from those of
infants and children [30].
Most in vivo experiments have been conducted with
young animals using various experimental designs. In
general, several groups of animals are involved: a control
group receiving a purified diet without any Pb; a group
receiving a Pb salt-based solution, such as PbAc, either
orally or intravenously (or both, if there are two groups),
at different dosages representing the Pb dose range of
the test materials; and, finally, a group administered with
different doses of the test materials. Similar Pb doses
from the test materials and from PbAc are necessary to
ensure that the slopes of dose–response curves for both
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applied usually includes low to high doses so that some
degree of active transport (saturable) is represented in
the blood compartment. Pb salts such as PbAc (soluble)
are used as references to compare test materials and cal-
culate bioavailability. Administering Pb salts intraven-
ously allows the absolute bioavailability [ABA] – the
fraction of Pb that enters the bloodstream (absorption
fraction) – to be calculated (Equations 1–2). If PbAc is
delivered orally, the relative bioavailability [RBA] – the
bioavailability of the test material relative to that of
PbAc – is calculated (Equation 3). The intravenous dos-
age for determining ABA is also used to set minimum
and maximum BLLs for a range of doses and to better
characterize Pb distribution in a steady state [39-41].
RBA is also called “oral bioavailability”, but relative to an
appropriate reference material (PbAc) [41,42]. RBA is
more informative, because it takes the exposure matrix
into account [43]. The ABA can be calculated, as
opposed to measured, through intravenous injections, by
multiplying the RBA by the Pb absorption fraction
(ABA) of PbAc administered orally (Equation 4).
Oral ABA calculation:
ABATM ¼ IDMoral TMIDMiv PbAc 
Doseiv PbAc
Doseoral TM
: ð1Þ
ABAPbAc ¼ IDMoral PbAcIDMiv PbAc 
Doseiv PbAc
Doseoral PbAc
: ð2Þ
Oral RBA calculation:
RBATM ¼ ABATMABAoral PbAc :
RBATM ¼ IDMoral TMIDMoral PbAc 
Doseoral PbAc
Doseoral TM
: ð3Þ
Link between ABA and RBA:
ABATM ¼ ABAoral PbAc  RBATM: ð4Þ
IDM – Internal Dose Metrics (BLL, Pb in tissues, etc.);
iv – intravenous; TM – Test Material.
The internal dose metrics [IDM] measured during
in vivo experiments can also vary. Several kinetic pools
for Pb in the human body with varying rates of turnover,
partly depending on the time elapsed since the adminis-
tration of the Pb dose, affect bioavailability estimation.
To address this, sequential blood samples can be col-
lected during the experiment, as well as blood and tissue
samples on the last day of the test. The tissue samples
most frequently collected are from the liver, kidneys,
and femurs. The amount of Pb stored in other parts of
the body is considered to be small, in the order of 4% of
total Pb measured in blood, bones, liver, and kidneys for
short-term experiments [44]. So, RBA calculation can bebased on Pb levels either in blood or in tissues: blood-
based RBA is calculated by measuring the ratio between
BLL following test material ingestion and BLL following
oral ingestion of PbAc for a similar dosage (Equation 3).
This ratio is measured under presumed steady state con-
ditions after repeated exposure, resulting in a stable
BLL, or at various times during the experiment to moni-
tor BLL evolution [44]. Similar ratios can be established
for bones, kidneys, and liver on the last day of the ex-
periment [45-47].
The most commonly used approach for evaluating bio-
availability, and a comprehensive one, is based on moni-
toring BLLs over the course of the experiment for
different dosages, as well as the Pb content in bones,
kidneys, and liver at the end of the exposure period for
different dosages. The “area-under-the-blood concentra-
tion versus time curve” [AUC] of BLL is then calculated
for each Pb dose and test material (Figure 1). The AUC
approach for BLL has the advantage of including the
whole dose–response relationship of the BLL over the
time of the experiment. However, the information it pro-
vides on the evolution of absorption over that period is
poor [48]. AUC BLL (e.g. μg×day/dL), bone Pb levels, or
other kinds of IDM for Pb salt and test material are then
fitted versus Pb dose. Identical absorbed doses of Pb
delivered to target Pb pools are assumed to produce an
equivalent IDM [40]. Bioavailability is determined by cal-
culating the ratio of Pb test material dose and the PbAc
dose that yields an identical IDM [40,49] (Figure 2). This
calculation is equivalent to Equation 3, since the IDM
for both the test material and the PbAc administered or-
ally cancel each other out:
Oral RBA based on equivalent IDM:
RBATM ¼ DosePbAc oral producing equivalent IDM to TMDoseTM oral producing equivalent IDM to PbAc : ð5Þ
(a)
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mathematical model for both the PbAc dose and the Pb
test material dose IDMs. Indeed, an IDM per unit of
absorbed Pb dose does not depend on the Pb source.
The best fit for bone, liver, and kidney Pb levels is usu-
ally linear, whereas for BLL/AUC, which increases
gradually and then reaches a plateau (steady state), the
best fit is non linear and varies [42,49]. Doses of Pb test
material and Pb salt producing the same IDM can be
calculated from the best fitting equations, and the bio-
availability ratio calculated for each endpoint studied
(AUC, BLL, Pb in bones, etc.). The BLL/AUC used for
this ratio is usually the point before the rate of uptake of
Pb from the test material starts to decrease owing to in-
creasing dosage [40]. The ratio can also be calculated for
a range of doses that reflects currently estimated expos-
ure. Finally, a point estimate can also be calculated,
which combines the bioavailability related to each of the
endpoints studied simultaneously, and is weighted
according to its uncertainty. However no significant dif-
ferences were shown between using only a BLL estimate
or a point estimate based on multiple IDM [42,49].Another way to evaluate bioavailability is to complete
a total mass balance. This method requires sequential
BLL sampling, as well as total collection of urine and
feces to recover all the excreted Pb. Pb content in feces
and urine is subtracted from total Pb intake, and pro-
vides an estimate of the body’s net retention [37]. Urine
samples represent the absorbed dose of Pb that is pri-
marily excreted, whereas fecal samples provide the frac-
tion of Pb that is unabsorbed [50]. When BLLs reach a
steady-state with multiple dosing, bioavailability can be
determined by calculating the ratio of total Pb in the
urine plus total Pb retained in the body to total Pb
recovered. Such results have limited value if the total net
excretions are underestimated. However, this method is
nearly non invasive for the test subject, and can provide
information on Pb accumulation in the body after
repeated exposure. This makes it useful for studies on
Pb uptake and Pb distribution in the whole body [48].
The method for calculating the bioavailability and
IDM on which it is based directly influences the bio-
availability estimates. Understanding these differences is
important when comparing results based on different
methodologies. An RBA based on BLL is unlikely to pro-
vide the same results as global bioavailability based on
the whole body’s Pb uptake derived from a complete
mass balance. If bioavailability is based on the blood
AUC, the results will be influenced by the duration of
the experiment and the timing of sampling. Further-
more, the interactions between Pb in soft tissues, bones,
and blood determine the fractional absorption, and thus
the bioavailability [51]. The timing of the sampling should
be chosen carefully, considering the evolution of BLL over
time and whether or not steady state is reached [52].
Experimental factors influencing Pb bioavailability
The in vivo experimental design parameters affecting the
estimation of Pb bioavailability include: the animal
model (species), its age, the addition of food, the dur-
ation of the experiment, and the dosage. The selection
of these parameters and corresponding bioavailability
results for published studies are summarized in Table 1.
Animal model
A major factor affecting bioavailability estimation is the
animal species used, and includes its age and its deve-
lopmental stage. Intra-species differences in anatomy,
feeding behavior, absorption rate, and digestion pro-
cesses influence the results. As shown in Table 1, rats,
piglets, and rabbits have been used to estimate Pb par-
ticle bioavailability. Pioneer studies used rodents and
rabbits to determine bioavailability and the risk to
infants/children [39,44,45,54,55,71-74].
Although rodents and lagomorphs are widely used and
well-known animal in vivo models, differences in their
Table 1 In vivo experiments on Pb particles and bioavailability results (2 pages)
REFERENCE SPECIMEN SUBSTRATE STATE, DURATION,
DOSE
RBA/ABA
Freeman et al. 1992 [45] Rats (7–8 wk) Mine wastes • Fed • 12.1±3.6-26.8±4.8 (blood RBA %)
• 30 d • 4.8±1.9-13.3±2.2 (bone RBA %)
• 0.12-24 mg Pb/kg bw/d • 0.6±3.1-13.6±3.1 (liver RBA %)
Dieter et al. 1993 [53] Rats (6–7 wk) Pb oxide, Pb sulfide,
Pb ore concentrate
• Fed • 69-93 (blood RBA %, Pb oxide)
• 30 d • ND-36 (blood RBA %, Pb sulfide)
• 0–100 ppm Pb • ND-10 (blood RBA %, Pb ore)
Freeman et al. 1993 [54] Rats (7–8 wk) Mine wastes • Fed • 0.36±1.04-7.32±1.57 (blood ABA %)
• 30 d • 0.51±0.15-2.25±0.23 (bone ABA %)
• 5 to 20 ppm Pb
Ruby et al. 1993 [55] Rabbits (12 wk) Mine wastes • Fast • 9±4 % Pb soluble in stomach
• 0.5-36 h
• 7.8 mg Pb/kg bw
Freeman et al. 1994 [39] Rats (7–8 wk) Mine wastes • Fed • 2.7±1.5 (% blood RBA)
• 30 d • 0.40±0.16 (% bone RBA)
• 0.12 to 24 mg Pb/kg bw/
d
• 0.55±0.68 (% liver RBA)
Schoof et al. 1995 [40] Rats (4 wk) Smelter soil • Fed • 41 (% blood RBA)
• 31 d • 20 (% blood ABA)
• 0.11-3.4 mg Pb/kg bw/d
Freeman et al. 1996 [44] Rats (~ 4 wk) Soil, Pb sulfide • Fed • 0.8-8.7 (soil, % RBA)
• 44 d • 1.2-5 (Pb sulfide,% RBA)
• 17.6-127 ppm
Lorenzana et al. 1996 [56] Swine (40–50 d) Tacoma smelter soil & slag • Fast (small dough) • Mean ABA§ (%, PbAciv): 10 (soil),
4 (slag)
• 0–7 d
• 34–567 μg Pb/kg bw
(single dose)
Casteel et al. 1997 [49] Swine (8–9 kg) Berm and residential soils • Fast (small dough) • 74-75 (point estimate RBA %‡)
• 15 d
• 71–732 μg Pb/kg bw/d
Casteel et al. 1997-1998# Swine Joplin smelter soil treated or
not with 1% phosphate
• Point estimate RBA (%): 59–67
(not treated) to 38–45 (treated 1%
phosphate)
Maddaloni et al. 1998 [38] Humans (21–40
yr)
Bunker Hill residential soil • Fast & Fed • Fasting state: 26.2±8.1 (% ABA)
• 30 h • With breakfast meal: 2.52±1.7
(% ABA)
• 250 μg Pb/70 kg bw
Ellickson et al. 2001 [57] Rats (0.18–0.2 kg) SRM 2710 Montana soil • Fast • 0.4-0.9 (% RBA)
• 3 d
• 7–8 mg Pb (single dose)
Brown et al. 2003 [58] Rats (3–4 wk) Urban soil treated with
biosolids (n=9)
• Fed • RBA not calculated in %
• 35 d
• 71–125 mg Pb/kg diet
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Table 1 In vivo experiments on Pb particles and bioavailability results (2 pages) (Continued)
Hettiarachchi et al.
2003 [59]
Rats (12 wk) Joplin soil treated or not with
Mn, phosphate, or CRYP
(n=15)
• Fed• 21 d • Blood RBA%: 34 (not treated);
19–33 (treated)
• 1–6 mg Pb/kg bw/d • Kidney RBA%: 48 (not treated);
19–39 (treated)
• Liver RBA%: 27 (not treated); 19–21
(treated)
• Bone RBA%: 34 (not treated); 20–24
(treated)
USEPA 2004, 2009 [60,61] Juvenile swine 2 Omaha smelter soils • Fast (small dough) • 83 & 96 (point estimate RBA %)
• 15 d
• 75–675 μg Pb/kg bw/d
Casteel et al. 2006 [42] Swine (5–6 wk) 19 soil or soil-like materials† • Fast (small dough) • 1-105 (point estimate RBA %*)
• 15 d
• 75–675 μg Pb/kg bw/d
Marschner et al. 2006 [62] Swine (70 d) 5 soils • Semi-fed (milk powder
after 5 h fast)
• 17-63 (RBA %)
• 28 d
• 0.1-3.2 mg Pb/kg bw/d
MSE Technology
Application 2006 [63]
Swine (5–6 wk) Smelter soil HER-2930 • Fast (small dough) • 82 (point estimate RBA %)
• 15 d
• 77–686 μg Pb/kg bw/d
Smith Jr. et al. 2008 [46] Rats (~ 21 d)
Micropigs (~ 30 d)
2 smelter soils • Fed • Rats RBA %: 88 (blood), 62 (bone)
• 30 d • Micropigs RBA %: 81 (blood),
68 (bone)
• 50 μg Pb/g diet
Smith Jr. et al. 2008 [47] Rats (~ 21 d) 5 soils • Fed • 85±48 (blood RBA %)
• 35 d • 91±12 (bone RBA %)
• 6.8-150 μg Pb/g diet
Bannon et al. 2009 [64] Juvenile swine 8 small arms range soils • Fast (small dough) • 108±18 (point estimate RBA %)
• 15 d
• 75–675 μg Pb/kg bw/d
Caboche 2009 Denys et al.
2012 [65,66]
Swine (28 d) 15 mining and smelting soils • Fast (small dough) • 6-100 (kidney RBA %)
• 14 d • 8–100 (urine RBA %)
• <1 to 8 mg Pb/kg bw/d • 9–100 (bone RBA %)
• 10–85 (liver RBA %)
Juhasz et al. 2009 [67] Swine (6–8 wk) 5 incinerator and urban soils • Fast • 10.1±8.7-19.1±14.9 (blood RBA %)
• 5 d
• 0.1-1.2 mg Pb/kg bw
(single dose)
Smith et al. 2011 [68] Adult mice 12 Pb impacted soils from
various sources
• Fast • 10±2.8-89±15.3 (blood RBA %)
• 48 h
• 0.1-1.7 mg Pb (single
dose)
RBA–relative bioavailability; ABA–absolute bioavailability; ND–not determined; §estimates include 0 & 100% in the confidence interval; ‡USEPA and Casteel et al.
point estimate [42,43]; #data from the Ruby et al. review [69]; †including soils tested by Schroder et al. [70]; *also available in USEPA [43].
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http://journal.chemistrycentral.com/content/6/1/138digestive systems compared to the human prevent direct
extrapolation to the Pb exposure of human children.
First, rodent stomachs have a smaller glandular region
than human stomachs, and consequently less surface
area for parietal cells secreting acid [48]. This results in
a higher stomach pH of 3.9 and 3.2 in the fasting and
fed states respectively [75]. In contrast, rabbits present a
relatively low pH of 1.6 in the fed state, which is signifi-
cantly lower than that of humans [76]. Also, the surface
area of the small intestine of a rat is about one-fifth the
size a human one, which implies decreased Pb bioavail-
ability, since some absorption mechanisms in the small
intestine are surface area-dependent [48]. Another sig-
nificant difference is that the rat’s small intestine is ma-
ture at weaning, unlike that of the human newborn, and
its Ca absorption capacity decreases rapidly within 30
days [48]. This results in a drastic decrease in the rat’s
Pb absorption rate, from about 80% between 0 and 30
days to about 50% between 1–2 weeks and 6–8 weeks
[30,51]. Several in vivo studies listed in Table 1 have used
rats aged 4 weeks and 6–7 weeks [39,40,44,45,54,57],
which may have been too old to be representative of the
high Pb absorption rates found in children 0–6 years old
[52]. Differences in the soils tested aside, the animal’s age
may actually explain the significantly higher blood RBA
(85-88%) observed in weaning rats aged 21 days [46,47],
compared to that of rats aged 4 weeks and older (0.8-41%)
[39,40,45,54]. Also, the 12-week old rabbits used by Ruby
et al. [55] may be more representative of adult digestive
conditions, as a 5-week old rabbit absorbs twice as much
Pb as an older rabbit [52]. The declining absorption rates
within a relatively short period constitute a challenge in it-
self, since bioavailability tests must extend over several
weeks owing to the half-life of Pb in blood. During a sub-
chronic testing period of 15–30 days, the weanling rat’s Pb
absorption can vary significantly, depending on its age at
the start of the testing period.
Specific behavior and defense mechanisms of rats and
rabbits also influence absorption. For example, in response
to exposure to Pb, rats lower their body temperature,
which decreases its RBA. Furthermore, the constant feed-
ing pattern of rats and rabbits and their cellulose-type diet
are not favorable to Pb dissolution in the stomach, as this
organ rarely empties completely, resulting in a pH buffer
effect and the constant availability of ligands for Pb ions
[48]. Finally, coprophagic behavior in both species can lead
to an inaccurate estimation of Pb bioavailability, because
of Pb recirculation. Coprophagy is essential to the assimi-
lation of all the nutrients necessary for the growth and de-
velopment of rodents and rabbits, which, if impeded, can
cause deficiencies in some minerals/vitamins that interfere
with Pb absorption. Biliary excretion is also greater in
rodents than in humans, and can generate errors in the es-
timation of Pb excreted and absorbed [40,46-48]. Despitethese differences, rats and rabbits are species commonly
used for in vivo experiments, and so are very well charac-
terized. Interpretation of the results, adjustments to them,
and extrapolation to humans may therefore be more ac-
curate than for other animal models that are less often
used in laboratories. Moreover, even with the marked dif-
ferences between their digestive systems and those of chil-
dren, these species remain highly useful for studying many
aspects of Pb exposure, such as estimating the potential
health risks of Pb (e.g., [77]).
Smith Jr. et al. compared Pb bioavailability in weanling
micropigs and rats for various test materials, concluding
that the micropig model is superior, because of a greater
Pb concentration in their tissues and the ability to detect
bioavailability trends in their bones, blood, liver, and
kidneys [46]. Juvenile swine appear to be a better surrogate
for predicting digestive and absorption processes in
infants, because of the similarities between them with re-
spect to: gastric hydrochloric acid (HCl) and protease
secretion; small intestine configuration; limited digestive
capacity, which impedes solid food digestion; and gut ma-
turity [34,78]. At birth, the digestive organs of both species
are comparable in size, and the anatomy of the stomach
and small intestine is similar. Also, although the immature
swine grows faster than the newborn/child, it remains at
prepubertal state throughout the experiment [41]. Similar
patterns for secretions of HCl, pepsin, and other enzymes
are present in the stomach, although gland distribution
differs. Stomach capacities for babies at birth, 2 weeks,
and 4 weeks approach piglet stomach volumes at 0, 10,
and 20 days. Finally, the length of the small intestine and
the microscopic gut structure of infants and juvenile swine
are similar [78]. Marked differences also exist in the cap-
acity of the digestive tract relative to the body weight of
the piglet, which is three times greater than the newborn’s.
The piglet’s stomach volume is 260 cm3, compared to 130
cm3 for infants of the same weight (5.75 kg). In the piglet,
the length of the small intestine increases dramatically
within the first ten days of life compared to that of the
newborn. This implies that adjustments need to be made,
notably in terms of increases in feed levels/dosage. How-
ever, the piglet’s gastro-intestinal [GI] tract is well charac-
terized, and the relationships between body weight and
stomach/small intestine weight/length are known, so that
adequate adjustments can be made. To account for the
fact that the juvenile swine grows seven times faster than
the human baby, intake is expressed relative to gut cap-
acity at similar developmental stages. This rapid growth
can be an advantage, since it provides an accelerated
model for postnatal human growth and development. Fi-
nally, the piglet’s size allows serial blood sampling without
stressing the animal [78]. However, the cost of conducting
piglet experiments can limit the use of this model to inves-
tigating multiple substrates.
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ments on piglets to estimate the bioavailability of soil Pb
particles, and from there the potential burden for infants/
children [41,79,80]. The juvenile swine model experimen-
tal procedure for assessing oral bioavailability from soils,
detailed in Weis et al. [41] and further developed by
Casteel et al. [42], was then applied to a wide variety of
soils [60,63,64,70], in some cases with modifications to the
original EPA procedure [46,62].
Conditions of dose and application
The dosage and its frequency are key factors affecting
bioavailability estimation [41]. Generally, a fixed quantity
of soil/dust is administered based on the estimated aver-
age daily soil/dust intake for children, which corre-
sponds to a variable Pb dosage depending on the Pb
content of the soil. However, for some animal models,
such as the rat, it is often necessary to increase dosages
in order to increase BLLs to detectable levels that permit
reliable differentiation between the PbAc and the test
material [45]. Bioavailability results obtained under such
conditions may be underestimated, as the rate of elimin-
ation of Pb at these high dosages could be much higher,
especially if they largely exceed the saturation concentra-
tion for active transport mechanisms in the gut [79].
Childhood soil/dust ingestion rates from hand-to-
mouth activity refer to small quantities ingested repeat-
edly during the day, resulting in a cumulative dose of
around 100 mg/day [52]. The bioavailability estimation
based on in vivo experiments is only valuable if the in-
gestion of the test material/PbAc and subsequent ab-
sorption by the test animal are representative of those of
children ingesting Pb from diet, soil, dust, paint, or
water [48,52]. Mushak’s review stresses that the dosages
for in vivo testing should be representative of children’s
exposure in terms of amount and number of ingestions
[52]. For example, the single high dose of 4.2 g of test
material in the Ruby et al. study [55] is not representa-
tive of normal children exposure, but more akin to soil
geophagia, a form of pica ingestion [52]. Realistic expo-
sures can be achieved by administering lower doses
twice daily, as performed in several swine studies in
Table 1 [42,49,60,61,63-65]. These studies suggest that
realistic dosages administered through multiple daily
ingestions are preferable, and represent a better simula-
tion of the exposure of the infant/child.
The choice of a fasting state or a fed state when
administering Pb doses is a major factor in calculating
bioavailability, since the stomach’s retention time and
pH, which are determining factors for Pb dissolution,
depend on that state. In vivo studies presented in Table 1
were performed either in fasting or fed state. The uptake
of PbAc is reduced by about half when Pb is adminis-
tered in food, rather than in a fasting state as in rat-based experimental studies [43]. Maddaloni et al. also
observed a decrease in RBA of about 24% from fasting
to feeding conditions in human adults after ingesting
contaminated soil [38]. The type of food also signifi-
cantly influences bioavailability, as shown by the wide
retention range associated with food type (3.5-56.8%), as
compared to 61.3% for fasting adults dosed with PbAc
[35]. That study concluded that Pb ingestion during
meals, as well as the presence of calcium, phosphate,
and phytate in the meals, notably decreases Pb bioavail-
ability three hours before and after ingestion. Indeed,
calcium, iron, and phosphate were shown to compete
with Pb for absorption through the intestine because of
similar uptake mechanisms, although Pb uptake was not
evidenced to occur via active iron transporters or cal-
cium channels [30,34]. Higher estimates of Pb bioavail-
ability were reported for liquids poor in nutritional
elements (33-72%), and the lowest for milk (11-17%),
traditional breakfast (0-8%), and calcium phytate (1-9%)
[35]. Given the significant impact of food, the fasting
state appears to be the conservative choice simulating
the worst, but still plausible scenario, since soil, dust,
and paint can be ingested by children during playtime
between meals. However, Pb particles ingested via drink-
ing water or formula, or incorporated into food during
cooking can be ingested in both the fasting and the feed-
ing state.
In vivo testing of Pb particles
Table 1 summarizes results from in vivo experiments
completed with Pb-contaminated soils and Pb paint
chips. Significant differences between the animal models,
their age, the dosages, the duration, and the calculation
method for generating RBA/ABA values must be taken
into account when comparing these estimates. The ex-
tent of fasting is highly variable in these studies, and
only a few studies were conducted in a complete fasting
state [38,55,57,67,68].
In conclusion, several experimental factors should be
considered, so that the results of in vivo Pb oral bioavail-
ability estimates using animal models can be extrapo-
lated appropriately to infants and children. In terms of
the animal model, juvenile swine carefully controlled for
age appear to be the best surrogate for human children.
Of all the reported experiments and procedures, the
conditions proposed by Casteel et al. [42,49], who used
juvenile swine over a subchronic period of 15 days with
0.5-5 g soil (75–675 μg Pb/kg bw/day) delivered twice
per day, appear the best suited for simulating the condi-
tions of ingestion of soil/dust/paint particles by infants/
children. The bioavailability calculation can be based on
BLL estimates, or on a point estimate combining mul-
tiple IDMs, such as the widely used AUC for BLL, and
the analysis of Pb accumulated in target tissues, such as
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formation on the distribution of body Pb and the inter-
action between accumulated lead in blood, soft tissues,
and bones.
In vitro bioaccessibility testing procedures
Bioaccessibility can be estimated at laboratory scale
using chemical extractions of Pb contaminated test ma-
terial in solution and under experimental conditions that
mimic the mixing and processing of GI fluids. The total
recoverable Pb is generally determined by subjecting a
subsample of the test material [TM] to strong acid di-
gestion, as, for example, in Method 3050 developed by
the USEPA for soils and sediments. In vitro bioaccessi-
bility [IVBA] is calculated as follows:
Pb IVBA ¼ mg Pb leached in extraction fluid per g of TM
mg total recoverable Pb per g of TM
:
ð6Þ
Several experimental factors affect the estimates of
bioaccessibility yielded by in vitro tests, and their impact
varies according to the type and form of the Pb sources
investigated. Choosing an adequate combination of these
factors is important for generating bioaccessibility results
that can be correlated to bioavailability results. Key fac-
tors include the physico-chemical conditions maintained
during the in vitro test, especially gastric and intestinal
pH, but also the co-presence of food, mixing conditions,
the solid to liquid [S/L] ratio, and the retention time.
Their relative importance is summarized in Table 2. Fi-
nally, it should be noted that we discuss all the tests in
this section, including those that were not correlated to
in vivo data. In fact, although they were not calibrated,
the latter tests provide an indication of the trends
observed when the parameters of an in vitro test are var-
ied, which makes it possible to rank the importance of
each of these parameters.
pH
Pb dissolution is very sensitive to pH. The correlation of
in vitro to in vivo results for weanling rats, for example,
has been shown to be critically dependent on the pH in
gastric simulations [74]. The solubility of mineral species
under the conditions that prevail in the stomach and
upper intestinal tract determines their bioavailability, the
factors affecting solubility being the mineral form, associ-
ation, inclusion, and size distribution. Overall, chemical
species formed under acidic conditions (e.g. Pb sulfate)
will tend to be more stable in simulated acidic conditions
and yield lower bioaccessibility values than those formed
under alkaline conditions, such as Pb oxide and Pb car-
bonate [69]. Notwithstanding the specific dissolution rates
of these forms of Pb, gastric pH stands out as a dominantfactor influencing bioaccessibility results for a similar par-
ticle size distribution. For mine waste impacted soil and
anglesite soil, Ruby et al. found that the rate of Pb dissol-
ution was linearly dependent on HCl content during the
first two hours of gastric retention [81]. Yang et al. mea-
sured Pb bioaccessibility values ranging from 50 to 80%
for soil with a gastric pH of 2, those figures dropping to 10
to 20% at pH 3 or 4 [83]. Drexler and Brattin showed that
pH was the most sensitive parameter in the RBALP: a
variation in pH between 1.5 and 3.5 resulted in a variation
in bioaccessibility by a factor from 2 to 7 that was only sta-
tistically significant above pH 2.5 [84]. Bruce et al. found
significantly higher rates of gastric bioaccessibility for
mine wastes tested at pH 1.3 (47%), as compared to pH
2.5 and 4 (17-18%) [94]. Oomen et al. concluded that gas-
tric simulation pH was the major source of variability be-
tween the results of a round robin test of five in vitro
models [82]. The stability of pH during the gastric phase
also appears to be critical [95]. In fact, Oliver et al. found a
higher bioaccessibility (26-46%) when the pH of the test
was maintained at 1.3 than when the test was performed
without any pH control (20-30%) [89]. Therefore, pH
should be controlled at the end of the gastric phase, in
order to provide the same acidic conditions for the various
substrates tested. Results from the RBALP, RIVM, and
UBM tests (calibrated) are only considered valid if the pH
at the end of the experiment does not exceed a set refer-
ence value [66,84,86].
Juhasz et al. showed that the solubility of PbAc salt
decreases greatly under simulated intestinal conditions
(pH 4–7.5), reflecting the gradual increase in pH at the en-
trance to the intestine: from nearly 100% at pH 1.5, the
IVBA decreases markedly between pH 4 and 6 to about
14.3±7.2% at pH 6–7 (Figure 3) [67]. Overall, initial concen-
trations in the range of 1 to 10 mg Pb/L did not influence
solubility in the pH 1.5-7.5 range; slight differences were
noted for high dosages of 5 and 10 mg/L with lower solu-
bility at pH 5.5, and small but significant increases in solu-
bility at pH 7.5. The steep decrease in PbAc solubility
between pH 4.0 and 6.0 corresponds to the gradual increase
in pH in the duodenum and jejunum, where most of the
absorption and transport of Pb cations and complexes is
supposed to take place [30,52]. Therefore, an intestinal
phase carried out at pH 5.0 may not give the same results
as an intestinal phase performed at pH 7.0. A realistic rep-
resentation of the intestinal phase would include gradually
increasing the pH and performing a series of sample collec-
tions during this increase, but doing so would be a huge
challenge and would introduce much variability.
Temperature
The kinetics of Pb dissolution is known to be affected by
temperature. However, for the conditions typical of in vitro
experiments, temperature is not as strong a determinant of
Table 2 In vitro tests design: main factors affecting bioaccessibility results
Parameters Degree of
Importance
General impact on IVBA% Notes References
(non exhaustive)
Gastric pH +++ - IVBA ↑ when pH ↓ - Check the pH increase at the end of
the G phase.
[69,81-84]
Intestinal pH +++ - ↓ IVBA as compared to gastric IVBA - Adjust intestinal IVBA to Pb salt solubility
during the intestinal phase
[65,67,85,86]
- Major ↓ IVBA from pH 4 to 6
- Increase in solubility of bile/pancreatin-Pb
complexes at pH 7.5- Slight ↑ IVBA at pH 7.5 compared to pH
6.0-7.0
Temperature - - No impact between 20°C and 37°C - May be important when enzymes are added [84]
Phases
simulated
+++ - Gastric IVBA > Intestinal IVBA - Adjust intestinal IVBA to Pb salt solubility
during the intestinal phase
[67]
Extraction + - IVBA ↓ in the range: centrifugation >
microfiltration > UF
- No difference between 0.2 and 0.45 μm
filtration
[84,87]
Fluid
composition
+ - Contradictory results (↑ or ↓ IVBA) - Physiologically based fluids may be important
when food is added
[55,67,85,88-90]
- Physiologically based fluids do not
seem important for the G phase - Bile/pancreatin would create soluble complexes
with Pb
Retention
time
++ - IVBA ↑ when gastric phase time ↑ - Lower impact on more soluble Pb forms:
IVBA plateau reached after 20–30 min
[55,74,88,91]
- No information on intestinal extraction
time effect
Mixing ++ - Aggressive mixing (Ar gas) ↑ IVBA - End-over-end agitation adapted to maximize
solid/fluid contact, but not too aggressive
[69,74,84]
S/L ratio
(g/mL)
+++ - IVBA ↓ with high S/L > 1/100 - High S/L ↑ the effect of TM on pH ↑ [83,84,92]
- No effect between low ratio 1/100 and
1/5000
- Low ratios (< 1/125) give poorer reproducibility
Food
addition
+++ - IVBA ↓ with food, except powdered milk - Effect variable depending on food type [62,87,88,93]
- Fed tests linked to lower recovery rates
+++ high importance, ++ moderate importance, + light importance, - no importance, based on the studies published to date.
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the digestive juices. Drexler and Brattin found no significant
difference between the RBALP results obtained at ambient
temperature and those at human body temperature for
seventeen test materials [84]. Most of the procedures apply
a 37°C temperature by default, since temperature is a fixed
parameter in the digestive process and closely mimics bio-
logical conditions.
Separation of the liquid from the solid
The separation method is an essential step in determin-
ing the bioaccessible Pb fraction [87], and the definition
of the separation limit between particulate and dissolved
Pb varies significantly in the literature and between
models. Extraction can be achieved by centrifugation
(e.g. [55,82,96]), centrifugation followed by filtration of the
supernatant (e.g. [83,94]), or direct filtration (e.g. [84,89]).
Others have used epithelial Caco-2 cells, in order to better
represent the intestinal wall morphology [97]. Also, an
aliquot of the digestion product can be analyzed directly,
based on the hypothesis that the analytical instrument will
only detect dissolved Pb [26,98].
In the absence of an extraction step, the digestion
product should be analyzed immediately. Centrifugationcan be applied at various combinations of rotational
speed and time, which can influence separation and im-
pact estimates of bioaccessible Pb. In filtration, the filter
cut-off varies. Several studies used 0.45 μm filters
[84,88,89], others used 0.2 μm filters [67,94], while the
TIM model recommends ultra-filtration [UF] [82,87].
However, filtration at the end of the intestinal phase
may bias results, since some filter materials are known
to absorb dissolved Pb at neutral pH, the absorbed
quantity varying with Pb concentration [99].
The impact of the various extraction methods identified
above can be classified by the magnitude of bioaccessibi-
lity, as follows: no extraction > centrifugation > microfil-
tration > UF > Caco-2 cells. Van De Wiele et al. applied
various extraction methods to the fed-RIVM, and bioac-
cessibility decreased from 31.5% (centrifugation) to 22%
(microfiltration) to 3.5% (UF) [87]. Bioaccessibility results
with UF were the closest to in vivo data on the same single
soil tested [38,87]; however, the authors stress that these
results are less reliable. Finally, Drexler and Brattin found
no significant difference between bioaccessibility estimated
with a filtration at 0.45 μm and one at 0.2 μm, suggesting
that non bioaccessible Pb would be mainly particles > 0.45
μm for the test materials in question [84].
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with pH, during the gastric and intestinal phases. Adapted from
[67].
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The primary function of digestive enzymes is the decom-
position of proteins (pepsin and trypsin) and carbohydrates
(pancreatic and small intestine enzymes), while bile emulsi-
fies lipids.
Oliver et al. showed that adding pepsin to the gastric
fluid decreased the amount of dissolved Pb by about 28%.
However, gastric pH did not remain constant, in fact, pH
was increasing from 1.3 to 3 after the addition of the dust
substrate, and this may be the factor responsible for
the decreased bioaccessibility [89]. Conversely, Medlin
compared bioaccessibility results using a physiologically-
based gastric fluid and diluted HCl, and found little diffe-
rence for cerussite, anglesite, and SRM 2710 at pH 1.5
[88]. However, at pH 2.8, the use of pepsin-based fluid
increased bioaccessibility significantly (by up to 42%). Fi-
nally, Drexler and Brattin showed that the addition of
enzymes was unnecessary for achieving a good in vivo-
in vitro relationship using the validated RBALP procedure,
which only simulates a gastric phase [84]. Consequently,
for tests simulating this phase, the addition of enzymes
appears unnecessary.
The simulation of physiological secretions may, how-
ever, be important for intestinal extraction. Ruby et al.
found an increase in bioaccessibility of about 20% with
the addition of organic acids and/or enzymes [55]. This
was explained by the chelating characteristics of organic
acids and by the binding of Pb to organic acids and
enzymes, which kept the Pb dissolved in the intestinal
fluid and prevented precipitation. Moreover, Juhasz et al.
explained the increase in Pb solubility at pH 7.5 (com-
pared to pH 6.0-7.0) by the formation of organo (pancrea-
tin/bile)-Pb complexes [67]. Oomen et al. have suggested
that the formation of Pb-bile complexes could increase
Pb2+ concentrations [85]. In addition, the bioaccessibility
results of Oomen et al. were about 10 to 40% higher forchicken bile than for ox or pig bile, which means that bile
will affect bioaccessibility differently, depending on its ani-
mal origin [90]. Finally, in the case of an in vitro procedure
simulating a fed state, the introduction of food may re-
quire the addition of enzymes and bile from both the
gastric and intestinal phases, since they play a role in food
degradation prior to absorption and in Pb complex forma-
tion [87].
Retention time
Retention times vary considerably between test method-
ologies and can impact the estimates of Pb bioaccessibil-
ity. Intuitively, for particles with limited solubility, longer
stomach retention time should enhance bioaccessibility,
since the extent of Pb dissolution increases with more
contact time at a given rate. Ruby et al. evaluated Pb
bioaccessibility in the stomach and intestine, and observed
an average increase of 4.8% between 30 min and 1 h dur-
ing the gastric phase, while an unsystematic decrease was
noted during the intestinal phase [74]. Gasser et al. studied
Pb dissolution in a stomach environment using a stirred
flow reactor, and observed an initial rapid increase in Pb
dissolution rate, which tended to decrease over time
(0–60 min) and pH (1–3) [91]. Both the time and pH in-
crement of this dissolution rate was substrate dependent.
Moreover, Ruby et al. stated that, if the dissolution of the
Pb-bearing mineral is controlled by a surface reaction rate,
then the transit time will control that dissolution, suggest-
ing that the impact of retention time in an in vitro test will
depend on the form of the substrate studied [69]. For low
solubility minerals, the dissolution kinetics would be con-
trolled by surface reactions, and so the major parameter
governing Pb release during digestion for these minerals
would be stomach retention time. This is illustrated by
Medlin’s results: less soluble Pb bearing minerals (angle-
site, pyromorphite, galena) exhibited the highest dissol-
ution rate, which continued to rise after the 1 h stomach
simulation, whereas more soluble Pb ones (e.g. cerussite)
generally reached a plateau after the first 20 min of the
gastric simulation [88]. In another study, however, Drexler
and Brattin applied 1, 2, and 4 h retention time to 11 sub-
strates from comparable sources (mining sites) and found
no significant differences [84].
Mixing
Determination of the mixing type and intensity depends
on the test material studied. Ruby et al. stated that mix-
ing controls the dissolution of Pb bearing materials
through transport mechanisms [69]. For more soluble
minerals, the kinetics of dissolution are controlled by
transport mechanisms in which dissolved ions are
quickly detached from the particle surface, accumulate,
and form a saturation solution at the boundary layer. In
addition, mixing conditions should be set to keep the Pb
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argon [Ar] injection, which efficiently kept the particles
in suspension, but this type of aggressive mixing may
overestimate bioaccessibility [74]. According to Drexler
and Brattin, end-over-end mixing is the most appropri-
ate for such experiments, because it maximizes the con-
tact between sample and fluid (substrate surface area),
and consequently Pb dissolution rate, and minimizes
contamination caused by interacting devices (paddle,
etc.) [84]. Moreover, it prevents the test material from
sticking to the bottom of the tube/beaker, as observed
for procedures using shaking water-bath (the authors’
observations in the laboratory).Solid to liquid ratio [S/L]
The S/L ratio is another major factor impacting Pb dissol-
ution and the resulting bioaccessibility estimation.
According to Dean and Ma, the most common S/L ratios
used for in vitro extractions vary between 1/2 and 1/250 g.
mL-1 [100]. Lower ratios, such as 1/1800 [101], 1/2160
[102], 1/5000 [92], and 1/16,667 [26], are also reported.
The gastric ratio should be limited to reduce the effect of
metal dissolution (observed for 1/5 and 1/25 ratios) and to
prevent Pb chloride crystal precipitation upon cooling (for
media containing over 50,000 mg Pb/kg) [84]. However,
gastric ratios as high as 1/2.5 [82], 1/10 (e.g. [55,89]) and
1/30 to 1/40 have been applied (e.g. [103,104]). Such ratios
may also increase the positive impact of the test material
on the pH, if the latter is not controlled, and consequently
underestimate bioaccessibility ([86]). For the same BMW
soil and similar PBET conditions at a 1/100 ratio, Ruby
et al. found higher bioaccessibility (9.5-35%) than at a 1/10
ratio (≤ 6%) [74]. The 1/10 ratio used in Oliver et al. may
have influenced the low bioaccessibility range found for
dusts (20-30%), compared to other studies on dust for
which Pb bioaccessibility generally exceeded 50% in the
gastric phase [89]. Yang et al. demonstrated that Pb bioac-
cessibility in soil increased by about 10% between gastric
ratios of 1/40 and 1/100 [83]. Hamel et al. had concluded
that Pb bioaccessibility was only slightly affected with
ratios between 1/100 and 1/5000 [92]. Medlin found that
the Pb bioaccessibility of SRM 2710 soil increases by about
11% between the ratios 1/100 and 1/500 [88]. Drexler and
Brattin standardized the procedure and recommended ap-
plying a ratio of 1 g of substrate per 100 mL fluid for
media containing Pb in amounts less than 5% by weight
(0.5/100 for substrates > 5 wt % Pb) [84]. Ratios below
1/125 are not recommended because of poorer reproduci-
bility (substrate heterogeneity, weighing errors), as well as
issues with the detection of low Pb concentrations during
subsequent analysis. The effect of the S/L ratio during the
intestinal phase has not been studied systematically, but
could influence the precipitation reactions and also thestability of the solution, which has been shown to be diffi-
cult to maintain.Food/substrate
The presence of food/substrate during digestion and its
type will influence bioaccessibility, and a systematic de-
crease in bioaccessibility following the addition of food
has been reported in most in vitro experiments, espe-
cially for gastric phase results. Indeed, dissolved Pb is
adsorbed on non-digested elements, and forms com-
plexes with some elements. Scheckel and Ryan found a
Pb bioaccessibility close to zero for highly soluble
hydrocerussite-based paint after the addition of a cola
soft drink to the gastric fluid [93]. These results were
explained by the reaction of soluble Pb with phosphates
in the drink to form pyromorphite solid. Results
obtained by Schroder et al. showed that the median
bioaccessibility without dough added was 36.3% and
0.62% for the gastric and the intestinal phase respect-
ively, while the test performed with dough resulted in
bioaccessibility medians of 27% and 0.58% [70]. The
swallow model performed by Brandon et al. in fasting
conditions estimated the Pb bioaccessibility of ‘real-life’
paint at about 10%, while it was about 4.5% for the test
performed with 4.5 g of infant food [101]. This decrease
may be partly attributed to the difference in the stomach
pH used to simulate a fasting state (1.6) or a fed state
(2.5), but the presence of food may also have an influ-
ence. Additionally, the RIVM and TIM models run with
and without solid food for the same soil resulted in
higher bioaccessibility values for the fasting state m
(32-47%) than for the fed state (RIVM: 24-39%; TIM:
7%) [87]. Retention times and pH were quite close be-
tween the tests performed with and without food,
suggesting that food would be partly responsible for this
decrease. Recovery efficiencies influence these estimates,
and the fed tests were linked to lower recoveries (70-93%)
than were observed in fasting tests (≥ 83%) [87].
Remarkably, some studies performed with whole milk
powder show the opposite trend, with an increase in
bioaccessibility in a fed state. Marschner et al.’s two-
phase enzymolyzis showed higher bioaccessibility for the
fed state (11-56%) than for the fasting state (2-21%) [62].
With controlled retention time, pH, and fluid formulas,
Van De Wiele et al. observed a higher bioaccessibility
with the addition of whole milk powder to the fluid for
the PBET and DIN tests (fed: 22-29%; fasting: 13-14%)
[87]. Medlin investigated different types of food (banana,
milk, oatmeal, and rice) and substrates (Pb phosphates,
slag, galena, and Pb oxide) [88]. Trends varied depend-
ing on the food, the Pb form, and the amount tested,
showing the huge challenges involved in the design of a
representative fed state [84].
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Various methods have been published to investigate the
bioaccessibility of Pb particles in environmental media,
using simple to more complex methodologies aimed at
reproducing to a varying extent the conditions in the di-
gestive tract to which the particles are exposed. These
methods can be classified in two categories:
1. Non physiologically based tests simulating the
conditions of acidic pH and retention time in the
stomach, without enzymes or other physiological
fluids representative of real digestive conditions (or
only additions that were shown to impact IVBA),
namely: HCl extractions, the Relative Bioaccessibility
Leaching Procedure [RBALP] or Simple
Bioaccessibility Extraction Test [SBET], the Solubility
Bioavailability Research Consortium procedure
[SBRC], and variants of these tests.
2. Physiologically based extraction tests which attempt
to simulate the physiological fluids and conditions of
the digestive tract, namely: the Physiologically Based
Extraction Test [PBET], the In Vitro Gastrointestinal
method [IVG], the RIVM model, the Unified Barge
Method [UBM], the DIN model, the TIM model, the
SHIME model, and variants of these tests, either
dynamic or static.
Table 3 summarizes the results obtained for the same
test materials using various in vitro procedures. Depend-
ing on the procedure applied, the estimated IVBA varies
widely, especially the intestinal IVBA. Results obtained
with different in vitro test designs should be compared
with caution, in light of the differences in testing condi-
tions discussed previously. A more important aspect to
consider is whether or not these tests provide estimates
of bioaccessibility that are useful for refining bioavail-
ability and Pb exposure assessments. In fact, the main
objective of a bioaccessibility test is to offer a rapid and
low cost alternative to bioavailability testing. Therefore,
the optimal bioaccessibility test should produce data that
can be adequately correlated to in vivo data. In vivo to
in vitro correlation [IVIVC] can be used to calibrate
in vitro testing conditions, which is highly desirable as it
would ensure that an in vitro method is an acceptable al-
ternative to animal investigations. These correlations are
usually presented as linear regression models, and their
strength will depend on the number of substrates tested
and the range of IVBA/RBA available. According to
Drexler and Brattin, a strong correlation is determined
by an R2 > 0.6 and a significant relationship with a slope
as close as possible to 1 [84]. However, it is suggested
that the correlation coefficient may be more important
than the slope, since a slope ≠ 1 does not impede linking
IVBA to RBA [105].Another important aspect to consider in the selection
of the in vitro testing procedure is the validation of the
in vitro test. In vitro procedures should ideally be sub-
jected to round robin testing to verify the ability of the
results to be accurately reproduced or replicated. Inter-
laboratory testing is needed to standardize the procedure,
so that it can be applied in any laboratory on multiple test
materials [65,84]. For example, the UBM procedure is
considered valid when the relative standard deviation
(RSD) of within-laboratory results and between-laboratory
results was ≤ 10% and ≤ 20% respectively [95]. Then, mul-
tiple low cost experiments can be completed and extrapo-
lated using existing data on animals and/or humans, and
can be expected to be semi-quantitatively accurate. In
vitro procedures that have not been calibrated or validated
can nevertheless be useful, but should be considered as
approximations and interpreted with caution.
In vitro test results compared to in vivo data
Table 4 lists in vitro tests that have been correlated to
in vivo data, including variants of the PBET and IVG
procedures: RIVM, UBM, RBALP, and SBRC.
PBET and IVG procedures
Numerous authors have used in vitro systems to esti-
mate the bioavailability of inorganic elements. The PBET
introduced by Ruby et al. [55,74] based on their previous
work, was the first test for Pb particles that used simu-
lated biological fluids in both the gastric and intestinal
phases, and that correlated the results to in vivo data. As
shown in Table 4, a synthetic gastric fluid composed of
HCl, pepsin, and organic acids is added to the soil sam-
ple in a 1/100 g.mL-1 ratio. Initial incubation is per-
formed at 37°C with varying initial pH (1.3, 2.5, 3.0, and
4.0), reflecting different digestion conditions under mix-
ing with argon. After an hour, the pH is progressively
adjusted to 7.0 using sodium bicarbonate [NaHCO3],
simulated intestinal fluids (pancreatin and bile) are
added, and mixing is continued for another four hours.
The mixture is then centrifuged and settled, and the
supernatant analyzed. A similar PBET test was devel-
oped by Medlin, using a comparable gastric S/L ratio
and the similar synthetic gastric fluid formula [88]. The
impact on the results of modifying the pH, time, particle
size, and food addition, as well as the addition of a two-
hour intestinal phase, was investigated. The final test
applied only a gastric phase at pH 1.5 for 1 h, with con-
tinuous pH measurement, a mixing step combining Ar
gas on the surface of the reaction vessel with the stirring
rod moving at 60 rpm, and an extraction via 0.45 μm
filtration. Brown et al. and Hettiarachchi et al. applied a
similar version of PBET, as recommended by Ruby et al.
[74], although the intestinal phase was either not simu-
lated or faster (1 h) [58,59] (Table 4).
Table 3 Comparison of bioaccessibility results obtained with the same test materials
MATERIAL TEST TYPE GASTRIC IVBA % INTESTINAL IVBA % REFERENCES
Montana PBET 67.3 [88]
SRM 2710 soil PBET 29±5 to 46±29 [92]
RBA 76%† PBET 54-62±1* [102]
PBET 76.1±11 10.7±2.3 [57]
PBET 30-35 [90]
RIVM 79±4 25±1 [96]
RBALP 75±5 [84]
UBM 75 27 [65]
Montana DIN 46±2 [82,90]
SRM 2711 soil SHIME 3±0.3
TIM 17±3
RIVM 11±2
SBET 90±2
PBET 10-20 (60 for chicken bile)
PBET 85±5 13±1 [96]
RBALP 84±6 [84]
UBM 80 33 [65]
Bunker Hill soil PBET 75 [88]
RBA adults 62±25%‡ PBET 70±11* [102]
RIVM 87.6 ± 8.4 45.4 ± 4.0 [86]
PBET 13±0.8 [87]
DIN 13.6±0.6
SHIME 2.0±0.1
RIVM 31.8±2.5-47.4±3.2
TIM 32.5±4.5
Flanders soil DIN 31±3 [82]
SHIME 4±1
TIM 13±3
RIVM 66±9
SBET 91±4
Oker 11 soil RBA 55%§ DIN 16±2 [82]
SHIME 1±0.1
TIM 4±1
RIVM 29±2
SBET 56±4
IVG 20 [62]
SBRC 66.8±2.3 62.9±11 [67]
IVBA–in vitro bioaccessibility;*bioaccessible Pb (mg) included Pb leached in G&I phases; †RBA on juvenile swine [65]; ‡RBA on human adults [38,86]; §RBA on juvenile
swine [62].
Tests simulating a fasting state.
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[74] procedure were calibrated for Pb in mine wastes
with previous in vivo studies on Sprague Dawley rats.
Only in vitro results of the gastric phase at pH 1.3 and
2.5 were linearly correlated to in vivo results (R2 = 0.93),with a slope closer to 1 at pH 2.5 [45,71-74]. The pro-
cedure by Medlin also showed that gastric bioaccessibil-
ity predicted in vivo juvenile swine data better than
intestinal bioaccessibility (Table 4) [88]. Bioaccessibility
estimates from the intestinal phase (tested for SRM 2710
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from in vivo calibration studies. Brown et al. observed a
significant relationship between gastric RBA reduction
and IVBA reduction following different Pb remediation
methods performed on the tested soil [58]. Finally, Het-
tiarachchi et al. observed a stronger correlation of the
RBA point estimates in rats with gastric IVBA, than with
intestinal IVBA (Table 4) [59]. This lack of strong and
significant correlations demonstrates the extent of the
challenges in relating intestinal phase results from PBET
to in vivo data, possibly due to precipitation reactions
and the complexity of the mechanisms involved in intes-
tine wall absorption.
Although the demonstration of a strong correlation with
an animal model is highly valuable, the significance of the
calibration is maximized if it is obtained using an adapted
animal model that can be used to estimate exposure
and risk assessment in human populations. The IVIVC
observed for the PBET using rats [59,74], although signifi-
cant, may not be as valuable for studying childhood expos-
ure, however, because of the in vivo test design (animal
model and/or dose administered), as underlined by Mushak
[52]. In contrast, the PBET later developed by Medlin was
correlated to in vivo data in juvenile swine [88], which are
considered to be a better model for simulating digestion
and absorption processes in children. In addition, this test
was performed on a significant number of soils (n=15)
using an extensive QA/QC protocol. Therefore, it appears
to be more reliable than the Ruby et al. initial PBET [74].
Nonetheless, this test has not been subjected to the inter-
laboratory validation and statistical analysis that would
demonstrate good laboratory reproducibility of the results.
The IVG model, initially developed for PAH and PCB
[106], was subsequently applied to Pb. It reproduces the
PBET gastric and intestinal phases using physiological
fluids, but the formulation of the fluids, retention time,
and pH are different (Table 4). Schroder et al. and
Marschner et al. compared the IVG results to in vivo
results on swine using the same soils [62,70]. The ab-
sence of IVIVC in the Marschner et al. (2006) study was
attributed to the technical difficulties during the intes-
tinal phase simulation. However, Schroder et al. did find
significant relationships between in vivo and in vitro
results performed with and without dough: blood-based
bioavailability was correlated to gastric in vitro results
(R=0.93; p < 0.001) and to intestinal in vitro results
(R=0.80; p < 0.001) with dough. In vitro tests performed
without dough showed significant correlation to in vivo
blood-based bioavailability in the gastric phase, but not
in the intestinal phase (Table 4) [70]. However, the
in vivo data used for this correlation were later corrected
by Casteel et al. and the USEPA [42,43], and so the rela-
tionship would need to be re-evaluated with the cor-
rected data prior to any use for other test materials.Finally, this test cannot be considered as a fully validated
standardized in vitro procedure, because of the limited
use of a QA/QC protocol and incomplete statistical ana-
lysis [84]. Nonetheless, it can be noted that, here again,
the highest correlation was observed with in vitro gastric
results.
RBALP and SBRC procedures
Considering the apparently good correlation of bioavail-
ability and gastric bioaccessibility and the limited benefit
of including an intestinal phase [88], a protocol reprodu-
cing only the gastric phase was developed in Dr. John
Drexler’s laboratory. The RBALP was proposed after
some investigation into the impact of temperature, con-
tact time, pH, and S/L ratio to maximize correlation to
in vivo data [84,88]. The RBALP includes an extraction
with a synthetic fluid composed of glycine and HCl at
37°C (1 h, pH of 1.5, 1/100 g.mL-1). End-over-end
mixing is performed (28±2 rpm), and separation is
achieved via filtration at 0.45 μm. The test also includes
criteria allowing for rigorous, reliable, and reproducible
results that are only considered valid if: (1) the pH at
the end of the extraction is within 0.5 units of the initial
pH, which ensures that glycine buffering capacity is not
exceeded; (2) the maximum holding time before analysis
is one week; and (3) a rigorous QA/QC protocol is
applied, including analysis of a bottle blank, a blank
spike, a matrix spike, a duplicate sample, and a control
soil at a 5-10% frequency. The test was applied to two
SRM materials and nineteen test materials through
round robin testing by four laboratories, and the results
were compared via a statistical analysis. Intra-laboratory
results showed good precision and agreement, with a
CV of 2-6%, and the laboratory results respecting SRM
standards were highly reproducible (CV of 7%). These
observations confirm good reproducibility, precision,
and standardization of the method.
As shown in Table 4, the RBALP was highly correlated
to in vivo juvenile swine results using the nineteen test
materials, including one NIST paint, galena, and soils
impacted by mining and smelting activities [42,84].
Moreover, it is easier to perform than the PBET, because
of the formulation of the synthetic fluids and the rapidity
of the test. The British Geological Survey adapted the
RBALP and renamed it the Simple Bioacessibility Extrac-
tion Test (SBET). The SBET protocol has been applied
with some modifications [83,107]. Others applied the
original RBALP [64,108,109]. The test applied to eight
soils of small shooting ranges also revealed results com-
parable to an in vivo swine study (Table 4) [64]. Consid-
ering the number of substrates tested with the RBALP,
which was calibrated with in vivo data on a recog-
nized representative animal model and the results con-
firmed through a validation method, a rigorous QA/QC
Table 4 In vitro procedures applied to Pb particles and compared with in vivo data for subsequent calibration (2 pages)
References Substrate Oral phase Gastric phase Intestinal phase Comparison with in vivo data
Ruby et al. 1993
PBET-GI [55]
Mine wastes 1/10 g.mL-1 2 h @ pH 7.0 • In vivo results on rabbits (1 sample): 10.7%
(blood based RBA at t = 1 h), and 9±4 %
(gastric solubility,t = 1.5 h)2 h @ pH 1.3 Pepsin;
organic acids; HCl
NaHCO3; pancreatin; bile
Ruby et al. 1996
PBET-GI [74]
Mine wastes Residential
soils Tailings
1/100 g.mL-1 4 h @ pH 7.0 • In vivo relative Pb bioavailability in rats
(based on BLLs, Y axis) correlation to IVBA
results from the G phase (X axis):
R2 = 0.93, n=7, intercept 3.2, slope 1.4
1 h @ pH 2.5 Pepsin;
organic acids; HCl
NaHCO3; pancreatin; bile
• Correlation with I phase: R2 = 0.76
Medlin 1997
PBET-G [88]
15 soils or soil-like materials
(EPA Region VIII)
1/111 g.mL-1 • In vivo point estimates in piglets (Y-axis) correlated to
in vitro results (X-axis):
1 h @ pH 1.5 Pepsin;
organic acids; acetic
acids; HCl
R2=0.63, n=15, intercept −8.21, slope 0.90, p < 0.001*
• Extensive QA/QC protocol
Brown et al. 2003
PBET-G [58]
Urban soil treated with
various biosolids (n=9)
1/100 g.mL-1 • In vivo bone bioavailability reduction % in rats
correlated to in vitro bioaccessibility reduction
with the treatment of soils (R=0.9)1 h @ pH 2.3 Pepsin;
organic acids; HCl
Hettiarachchi et al. 2003
PBET-GI [59]
Joplin soil treated or not
with Mn, P, or CRYP (n=15)
1/100 g.mL-1 1 h @ pH 6.5 • In vivo point estimate RBA in rats (Y-axis) correlated to
in vitro results (X-axis)
1 h @ pH 2.0 Pepsin;
organic acids; HCl
NaHCO3; pancreatin; bile
G phase: R2=0.95, intercept 11, slope 0.82
I phase: R2=0.77, intercept 12, slope 1.87
Schroder et al. 2004
IVG [70]
18 soils (EPA Region VIII) 1/150 g.mL-1
1 h @ pH 1.8 Pepsin;
NaCl; HCl
1 h @ pH 5.5
Pancreatin; bile; NaHCO3;
decanol
• In vivo blood RBA (X-axis) in piglets correlated
(p < 0.001) to in vitro data (Y-axis)†:
- G (R=0.93) & I (R=0.80) results, with dough
- G results no dough (R=0.89)
• Best correlation for G phase with dough: R2=0.86, n=18,
intercept 2.97, slope 0.39
Marschner et al. 2006
IVG [62]
5 soils, with or without
milk powder
1/40 g.mL-1 6 h @ pH 7.5 • Absence of correlation between in vivo bioavailability in
piglets and in vitro results
2 h @ pH 2.0 Pepsin;
NaCl; HCl
NaHCO3; trypsin; bile;
pancreatin; urea; inorganics
Oomen et al. 2006
RIVM [86]
11 soils or soil-like material
(EPA Region VIII)
5 min @ pH 6.5 1/37.5 or 1/375 g.mL-1 2 h @ pH 5.5-6.5 • In vivo point estimates in piglets (X-axis) correlated
to relative in vitro fasted model results (Y-axis):
2 h @ pH 1.0-2.0 (in)organics, pancreatin,
bile, BSA, lipase, CaCl2
G phase: R2=0.68-0.79, intercept 0, slope 0.79-1.08
(in)organics, mucin,
uric acid, alpha-
amylase
I phase: R2=0.66-0.81, intercept 0, slope 0.69-1.16(in)organics, pepsin,
mucin, BSA
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Table 4 In vitro procedures applied to Pb particles and compared with in vivo data for subsequent calibration (2 pages) (Continued)
Drexler and Brattin 2007;
USEPA 2007
RBALP [43,84]
19 soil-like materials from
EPA region VIII,
1/100 g.mL-1 • In vivo RBA point estimates in piglets (Y-axis)
correlated to in vitro results (X-axis) : weighted
R2=0.924, n=19, intercept −0.028, slope 0.878, p < 0.0011 h @ pH 1.5
Glycine; HCl • Extensive QA/QC protocol and statistical analyses
• Precision 7% within samples, and 4-6%
within laboratories (round robin testing)
Bannon et al. 2009
RBALP [64]
8 small arms range soils 1/100 g.mL-1 1 h @ pH 1.5 • In vivo point estimates on piglets: 108±18%
• In vitro results: 83±1-100±3%
Glycine; HCl
Caboche 2009 Denys
et al. 2012
UBM [65,66]
14 mining and smelting
soils
5 min @ pH 6.5 1/37.5 g.mL-11 h @ pH
1.2-1.7
4 h @ pH 5.8-6.8 • In vivo kidney RBA in piglets (X-axis) correlated
to in vitro results adjusted by PbAc solubility in the G
and I phases (Y-axis):(in)organics, pancreatin, bile,
BSA, lipase, CaCl2
G phase: R2=0.93, intercept 1.10, slope 1.86, p < 0.01(in)organics, mucin,
uric acid, alpha-amylase
I phase: R2=0.89, intercept 1.09, slope 1.09, p < 0.01(in)organics, pepsin,
mucin, BSA
Juhasz et al. 2009
SBRC [67]
5 incinerator & urban soils;
5 soils from Marschner et al.
[62]
1/100 g.mL-1
1 h @ pH 1.5 Glycine, HCl
4 h @ pH 6.5
NaOH, pancreatin, bile
• In vivo blood RBA in piglets (Y-axis) correlated
to relative in vitro data for the I phase
(X-axis):R2=0.53, intercept 1.98, slope 0.58
(urban & incinerator soils)
R2=0.47, intercept 29.5, slope 0.42
(soils from Marschner et al., 2006 study)
Wragg et al. 2011
UBM [95]
12 soils (mining, composite,
phosphate-treated), 1 dust
5 min @ pH 6.5
(in)organics, mucin,
uric acid, alpha-amylase
1/100 g.mL-1 2 h @ pH
1.2-1.4
4 h @ pH 6.3±0.5 (in)
organics, pancreatin, bile,
BSA, lipase, CaCl2
• In vivo RBA in piglets (X-axis) correlated to
in vitro results adjusted by PbAc solubility in
the G and I phases (Y-axis):
(in)organics, pepsin,
mucin, BSA G phase: R2=0.61, slope 0.78, median RSD 4%
within samples, 33% within laboratories
I phase: R2=0.57, slope 0.38, median RSD 15%
within samples, 81% within laboratories
Smith et al. 2011
RBALP [68]
12 soils impacted from a
variety of Pb sources
1/100 g.mL-1 1 h @ pH
1.5 Glycine, HCl
• In vivo blood RBA in mice (X-axis) correlated to relative
in vitro data (Y-axis):
R2=0.78, intercept 30.207, slope 0.69
Smith et al. 2011
SBRC [68]
12 soils impacted from a
variety of Pb sources
1/100 g.mL-1 1 h @ pH
1.5 Glycine, HCl
4 h @ pH 6.5 NaOH,
pancreatin, bile
• In vivo blood RBA in mice (X-axis) correlated to relative
in vitro data (Y-axis):
R2=0.88, intercept −7.02, slope 1.06
(SBRC, I phase results)
IVBA–in vitro bioaccessibility; RBA–relative bioavailability; G–gastric; I–intestinal; RSD–relative standard deviation; *relationship with corrected EPA in vivo data from [84]; †in vitro-in vivo relationship not performed with
EPA corrected data (in vivo bioavailability or bulk Pb concentrations).
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http://journal.chemistrycentral.com/content/6/1/138protocol, and round robin testing, this test stands out as
a reference for application to other test materials. How-
ever, as underlined by the USEPA and Juhasz et al., al-
though the substrates used for calibrating this procedure
were numerous and originated from various sources,
they do not represent the variety of Pb particles that
exist in the environment. Also, they are made up of a
significant number of substrates at mining sites for
which Pb dissolution is limited during the gastric phase
[43,67]. Therefore, the RBALP IVIVC may not hold for
any other test material. Specifically, the RBALP applied
to substrates containing more soluble forms of Pb than
those found on mine sites, which partially precipitate/
react during the intestinal phase, may overestimate Pb
bioavailability [67]. Finally, results performed on soils
following remediation with phosphates showed a better
IVIVC with IVBA results performed at pH 2.5, suggest-
ing that the RBALP would give more valuable results at
pH 2.5 for evaluating soil remediation effectiveness
[110,111].
To respond to these concerns, Juhasz et al. added an
intestinal phase to the RBALP and compared the results
obtained for the gastric and intestinal phases to in vivo
bioavailability results on juvenile swine [67]. The SBRC
intestinal test simulates a gastric phase identical to that
of the RBALP, except that the agitation is performed at
40 rpm and the filtration on 0.2 μm filters, and then a
4-h intestinal phase is simulated at pH 6.5 with the
addition of NaOH, bile, and pancreatin. In order to take
into account precipitation reactions occurring during
the intestinal phase and better relate intestinal IVBA to
in vivo results, a relative intestinal IVBA was calculated.
This was adjusted with the solubility of PbAc at pH 6.5
in the synthetic fluid, which was estimated at about
10-20%, as compared to 100% during the gastric phase
at pH 1.5 (Equation 7). The application of an intestinal
pH of 6.5 was justified by the fact that PbAc solubility
was quite stable between 6.0 and 7.0, making the results
more robust.
Relative Pb IVBA ¼
in vitro PbTM
total extractable PbTM
in vitro PbPbAc
total PbPbAc
: ð7Þ
Gastric IVBA and absolute intestinal IVBA were
poorly correlated to in vivo data for the five soils tested,
while relative intestinal IVBA was satisfactorily corre-
lated (R2 = 0.53). Although based on a weak fit (R2 =
0.12), and on few test materials, the authors state that
the slightly negative Pearson correlation coefficient
observed for the gastric phase may indicate an overesti-
mation of the gastric phase estimates for some Pb forms.
Applied to the same soils tested in the Marschner et al.
study [62], relative intestinal IVBA estimates were well
correlated to blood RBA on piglets, unlike the IVGresults obtained by Marschner et al. [67]. This suggests
that the calculation of relative bioaccessibility is a better
RBA predictor. Interestingly, Smith et al. tested soils
with a wide range of bioavailability (10-83%) and report
excellent correlations between in vivo mouse data and
both the RBALP test and the SBRC-intestinal test
(Table 4) [68]. The slightly lower correlation obtained
using the RBALP is explained by the overprediction of
the RBA using this test for some soil types. This over-
prediction occurs because the presence of iron reduces
the intestinal estimates, but not the gastric estimates,
and so, the iron soil results correlated better using the
SBRC-intestinal test [68]. It should be noted, however,
that these conclusions were based on a comparison with
mouse in vivo data, which is a less adequate animal
model than the juvenile swine model. The IVIVC was
then applied to the SBRC relative bioaccessibility results
for thirty-one peri-urban soils, and compared to bio-
availability predictions using the USEPA regression
equation [43] on the SBRC results for the gastric phase.
The bioavailability predictions were in agreement for
shooting range soils, however different predictions were
found for soils with high iron content, incinerator soils,
historical fill soils, gasworks soils, and gossan soils
(Fe-oxide rich soils). Overall, the RBALP relationships
applied to the SBRC gastric results yielded more conser-
vative bioavailability predictions than when the SBRC
relationships were applied to the relative intestinal
results [112]. This suggests that the addition of an intes-
tinal phase to the RBALP, along with the use of relative
bioaccessibility instead of absolute bioaccessibility, may
yield bioaccessibility estimates that are closer to actual
bioavailability results for some soil matrices. Nonethe-
less, as emphasized previously, additional inter-laboratory
testing, statistical analysis, and further testing on juvenile
swine (N=5) would be desirable to reinforce and
standardize the SBRC-intestinal test, since, unlike the
RBALP, this procedure has not yet been validated. We
conclude that, while some refinements could be added to
the RBALP, this test is the one that has been more
thoroughly validated, and therefore is the most reliable.
RIVM and UBM procedures
The RIVM digestion model includes five minutes of
simulated contact with saliva, followed by gastric and in-
testinal phases (two hours each) with end-over-end rota-
tion at about 55 rpm in the presence of complex fluids.
Simulation of the salivary phase is not generally added
to in vitro models, because of the relatively short dur-
ation and neutral pH of this step. However, this step
may be relevant when food is added, which is considered
in the RIVM. For the test performed in the presence of
food (macaroni, infant formula), adjustments are made
in pH and fluid compositions to represent ‘stimulated’
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NaHCO3 (Table 4). As for the RBALP, the test procedure
is rigorously controlled for pH: 2.0 for the gastric phase,
and 6.5 for the intestinal phase. Extraction is performed
by centrifugation at 3,000 g and the pellet is kept for
analysis and mass balance [82,86,87]. Bioaccessibility
results for the fasting case were adjusted to PbAc solu-
bility during the intestinal phase (relative IVBA) and
compared to the USEPA data on juvenile swine on
eleven soil-like materials. The relationship found was sig-
nificant for the two S/L ratios tested (1/37.5 and 1/375 g.
mL-1), for either the gastric or the intestinal phase [86].
The test was further applied in other studies [96,103].
Nonetheless, calibration of the RIVM was performed with
bioavailability data from soils used for the RBALP calibra-
tion. It would be desirable to test the relationship with
soils from more widely varied sources to verify this
calibration.
The Unified BARGE Method (UBM) was developed by
the Bioaccessibility Research Group Europe (BARGE)
with the aim of selecting and standardizing a common
procedure for bioaccessibility testing, for several trace
elements (Pb, arsenic, cadmium, and antimony). In the
UBM, which is similar overall to the RIVM, the reten-
tion time of the gastric phase is reduced to 1 h, and it is
increased to 4 h for the intestinal phase [86]. IVBA
results obtained with this approach for Pb were compared
to in vivo RBA on juvenile swine for fourteen mining and
smelting soils. Gastric and intestinal bioaccessibility
showed strong IVIVC for Pb, arsenic and cadmium
(Table 4) [65,66]. Therefore, the UBM could be applied for
estimating the Pb, cadmium, and arsenic RBA for a single
test material, and at the same time, which is an important
advantage. This again suggests that the addition of the in-
testinal phase can be successfully linked to RBA results
using the relative IVBA. However, in another study, results
from the intestinal phase were not considered reliable for
13 other test materials, and those results did not meet any
of the criteria set for validation (Table 4) [95]. Denys et al.
concluded that the stomach phase of the UBM, carefully
controlled for pH, produces IVBA results that are very
comparable to juvenile swine RBA values [66]. Therefore,
the addition of the intestinal phase, although possible,
does not appear essential, and also complicates the test
and its validation. The gastric phase of the test was vali-
dated for Pb, cadmium, and arsenic, and showed a signifi-
cant IVIVC and reliable repeatability of the results [66].
An inter-laboratory trial was not able to fully validate the
test for good reproducibility (between laboratories) for Pb.
Nonetheless results suggest that a tight control of the gas-
tric pH during extractions would allow for a complete val-
idation [95].
The simulation of both the gastric and the intestinal
phase greatly impacts the estimates of Pb bioaccessibility.Bruce et al. measured a bioaccessibility of 47% for the
mine wastes at the end of the gastric phase, and these
values dropped to 7% at the end of the intestinal phase
[94]. The same range of decrease in bioaccessibility was
observed in other studies [67,113-115]. Results using Pb-
ISE and DPASV in chyme following GI in vitro digestion
showed that the free Pb2+ is indeed negligible, and that
most of the Pb was present as Pb-phosphate and Pb-bile
complexes in dynamic equilibrium with solubilized Pb
[85]. This solubilized Pb is largely removed from the solu-
tion by precipitation or adsorption on non-digested and
compatible particles [67,74]. These observations show that
Pb bioaccessibility could be overestimated if limited to the
gastric phase. However, significant experimental chal-
lenges arise from the precipitation reactions, the gradual
pH increase and parallel absorption, the eventual
adsorption of soluble Pb on non-digested particles, and
the increase of labile complexes that are difficult to main-
tain in equilibrium in the intestinal chyme [74,85]. Precipi-
tation conditions may not be as well simulated in a closed
system as in the gut, which is a thermodynamically open
system [52], but spiking and correction for recovery could
account for these losses. Comparison of Pb speciation by
XANES after the gastric and intestinal phases has
clearly shown the dominance of solubilized Pb after the
gastric phase and the importance of the presence of co-
precipitation with amorphous iron in soils containing
iron oxyhydroxides [68]. To address some of these con-
cerns, intestinal bioaccessibility can be adjusted relative
to estimates of a soluble Pb form (e.g. PbAc), at a ‘stable’
intestinal pH (6.0-7.0) (Figure 3) [67]. With this adjust-
ment, relative bioaccessibility estimates from the intes-
tinal phase are slightly lower than the gastric
bioaccessibility estimates, and seem to better relate to
in vivo data [67]. However, results of tests simulating
the gastric phase only are still more reliable, given that
these tests are fully validated. Also, considering the dif-
ficulties associated with adding an intestinal phase, and
although significant IVIVC can be obtained with intes-
tinal results, full validation of the test with good repeat-
ability and reproducibility would be quite challenging.
To refine intestinal in vitro testing, further knowledge
on the exact sites where Pb absorption takes place along
the gut and at which pH would be necessary, so that the
critical steps of the intestinal phase could be better
reproduced.
In conclusion, the RBALP appears to be the best test
yet devised for estimating the potential for childhood ex-
posure to multiple Pb sources, even though it is not fully
physiologically based. This test is the most suitable for
the cost effective testing of multiple sources of Pb parti-
cles. It is likely to overestimate bioavailability for some
test materials, and will produce a conservative IVBA es-
timate for these materials. However, the test is relatively
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data on the best suited animal surrogate for childhood
digestive conditions. Moreover, it is the only procedure
that has been validated through a complete statistical
analysis and round robin testing. Consequently, the
RBALP is standardized and can be applied in many la-
boratories on multiple test materials. The gastric phase
of the UBM, which is currently in the process of being
fully validated, is a pertinent alternative to the RBALP,
as it tests the IVBA of three elements in the same
procedure.Tests not compared with in vivo data
Several in vitro tests that have not been compared with
in vivo data have been proposed. These tests are import-
ant, since they may be validated in the future or be use-
ful for studying factors influencing Pb bioaccessibility
and bioavailability. Table 5 and Table 6 summarize the
various parameters applied in some of these tests either
not physiologically based (Table 5) or physiologically
based (Table 6).
Procedures that are not physiologically based (Table 5)
include a large number of batch acid extractions using
dilute HCl performed at various S/L ratios, durations,
and pH. Since 1994, HCl extraction has been a standard
method for assessing the toxicity of toys used to estab-
lish the European Standard on the Safety of Toys. The
toy material is reduced to a particle size < 500 μm and
added to an HCl solution using a 1/50 g.mL-1 ratio (pH
1.5; 37°C; 2 h) [50,129]. As pointed out by Le Bot et al.
[122], such tests may be helpful in preventing Pb poison-
ing. In fact, Pb leached during HCl extractions simulating
stomach conditions may provide a more relevant indica-
tion of potentially bioavailable Pb than standard total Pb
extractable measurements on wastes and solids. Some
sources could have high values of total extractable Pb even
though it is poorly soluble in the stomach, or, inversely,
they could impair the interpretation of BLLs and environ-
mental Pb levels.
Among the physiologically based models presented in
Table 6, many are modifications of the PBET, IVG, or
RIVM procedure. The German method, E DIN 19738
[DIN] mimics gastrointestinal digestion for infants/chil-
dren, in a fasting case or a fed state, through the
addition of whole milk powder. Gastric fluids are com-
posed of a mixture of pepsin, mucin, and HCl. Intestinal
fluids contain bile, trypsin, pancreatin, and phosphate
buffer. The gastric phase takes place at pH 2 over 2
hours, and a pH of 7.5 is applied to the intestinal phase
over 6 hours. Extraction is achieved by a two phase cen-
trifugation at 7,000 g, decantation, and analysis of the
supernatant [82,87]. Although somewhat laborious, DIN
appears to be a relevant method, as there is a need for atest with whole milk powder for infants exposed to Pb
particles in drinking water via baby feeding bottles.
The TIM, SHIME, and flow-through methods using
online extractions are dynamic, physiologically based
tests [87,130,131]. The TIM model (or TNO GI model)
mimics the contact with saliva and further GI digestion
by the progressive addition of fluids, the progressive ad-
justment of pH, and the simulation of peristaltic con-
tractions. Gastric pH and retention times are adjusted
differently if the simulation is aimed at representing a
fed state (pH decreases gradually from 5 to 2 over 90
min) or a fasting state (pH decreases gradually from 4.5
to 1.8 over 40 min). Then, intestinal fluids are added at
1 mL/min to increase the pH from 6.5 to 7.2, at which
point ultra-filtration is performed. This model has been
validated with in vivo dissolution profiles of drugs with
or without food; however, it was not calibrated for Pb
particles [82,86,87]. The SHIME (Simulator of Human
Intestinal Microbial Ecosystem of Infants) model, devel-
oped in Belgium, simulates 3 h gastric and 5 h intestinal
digestion in the same reactor (150 rpm). Gradients of
pH can be applied if a series of reactors is used (dynamic
model), and a phase including a mixed microbial com-
munity can be added to the model [82,132]. Constant
stomach retention times are applied for fasting condi-
tions (pH ~ 2.0) and fed conditions (pH ~ 4.0) [87].
Centrifugation at 7,000 g is conducted and the super-
natant is analyzed. The pellet is then digested to mass
balance [82]. However, these procedures cannot be used
routinely to measure Pb bioaccessibility on Pb particles
since they take too long to perform and are highly com-
plex. Nevertheless, it appears that they could be highly use-
ful for studying specific factors affecting Pb bioavailability
that have been poorly studied up to now, such as the effect
of bacteria.
Bioavailability/bioaccessibility of Pb particles in relation
to Pb speciation, particle size, and surrounding matrix
Physical and chemical aspects of Pb particles are major
factors influencing the dissolution of particles containing
Pb. Table 7 summarizes the IVBA results for calibrated
procedures, and shows that bioavailability and bioaccessi-
bility results vary widely with the test material: from 1.7-
6% for galena to 100% for shooting range soil, which is in
agreement with the in vivo swine data [42,64,68,84,86],
and from 1.5 to 100% for tap water particles [29]. Pb was
also found to be highly bioaccessible in NIST Paint
(75-86%), which is in agreement with previous epidemio-
logical studies referenced in Mushak [30]. In addition, Pb
is generally highly bioaccessible in smelter soils, with
about 68-69% for some Omaha community soils, and
about 70-85% for the Herculaneum smelter [61,63], and
34-90% for ten smelting soils from northern France [65].
However, variability in the bioavailability and bioaccessibility
Table 5 Examples of variants of non-physiologically-based in vitro procedures (not calibrated) applied to Pb particles
GENERAL GASTRIC INTESTINAL
Reference Mixing T°C Extraction S/L (g.mL-1) Time, pH Fluid Time, pH Fluid
Sheppard et al. 1995 [116] Filtration 0.5 μm 1/167 24 h, pH 2.0 HCl
Gasser et al. 1996 [91] Stirred-flow reactor 24°C Filtration 0.22 μm 1/100 1 h, pH 1.0 to 3.0 HCl, ammonium acetate
Gasser et al. 1996 [91] Horizontal shaker 24°C Centrifugation
(400 RCF; 10 min)
1/200 1 h, pH 1.0 HCl
Rieuwerts et al. 2000 [117] Inversion by hand 5 times
at t = 1h
Ambient Centrifugation
(2,000 rpm; 2 min)
1/100 2 h, pH 1.2 HCl
Yang et al. 2001 [118] Rotation 30 rpm 37°C Filtration 0.2 μm 1/100 1 h, pH 2–2.5 HCl
Mercier et al. 2002 [119] End-over-end 30 rpm, at
20 min intervals, for 20 min
35-39°C Decantation, filtration 1/22 160 ±10 min,
pH 6.0 to 2.0
HCl, acetic acid
Yang et al. 2002 [120] Rotation 30 rpm 37°C Filtration 0.2 μm 1/100 1 h, pH 2.0 HCl
Scheckel and Ryan 2003
[93]
Continuous stirring 37°C Filtration 0.45 μm 1/160 1 h, pH 2.0 HCl 5 h, pH 7.0
Yang et al. 2003 [83] End-over-end,30 rpm 37°C Decantation, filtration
0.45 μm
1/40 and
1/100
1 h, pH 1.5 to 4.0 HCl, glycine 3 h, pH 7.0 NaHCO3
Beak et al. 2006 [121] Variable speed mixer
(150 rpm); 2 mL/min Ar
37°C Filtration 0.45 μm 1/167 2 h, pH 1.8 HCl 4 h, pH 7.0 NaOH
Turner and Simmonds 2006
[98]
Ambient 1/100 Overnight HCl, pepsin
Bosso and Enzweiler 2008
[107]
Orbital, 100 rpm 37°C Centrifugation
(5,000 rpm; 20 min)
1/100 1 h, pH 1.5 HCl, glycine OR HCl,
pepsin, NaCl
2 h, pH 7.0 NaHCO3
Le Bot et al. 2010, 2011
[122,123]
Ultrasonication 37°C Filtration 0.45 μm 1 h, pH 1.5 HCl , 0.75-1.4% diluted
Rasmussen et al. 2011
[124]
37.5°C Centrifugation
(5,000 g, ≤ 10 min)
1/2000 2 h, pH 1.5 HCl
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Table 6 Examples of variants of physiologically based in vitro procedures (not calibrated) applied to Pb particles (2 pages)
GENERAL ORAL GASTRIC INTESTINAL
References Mixing Extraction Time,
pH
Fluid S/L
(g.mL-1)
Time, pH Fluid Time, pH Fluid
Sheppard et al. 1995
[116]
Centrifugation,
filtration 0.2 μm
4 h, pH 2.0 NaCl; pepsin; HCl 18 h, pH 7.5 NaHCO3; NaCl; bile;
pancreatin; α-amylase
Berti and Cunningham
1997 [125]
Stir bar 1/100 1 h, pH 2.5 Pepsin; organic
acids; HCl
2 h, pH 7.0 NaHCO3; pancreatin;
bile
Davis et al. 1997 [126] Wrist action
shaker
Centrifugation
(2,100 g; 25 min)
1/10 2 h, pH 1.3 Pepsin; organic
acids; HCl
2 h, pH 7.0 NaHCO3; pancreatin;
bile
Hamel et al. 1998 [92] Shaking
water bath
Centrifugation
(1,380 g; 10 min)
1/100 to
1/5000
2 h NaCl; pepsin; HCl
Hamel et al. 1999 [102] Water bath,
90 cyc/min
Centrifugation
(906 g; 10 min),
filtration 0.45 μm
5 s,
pH 5.5
Mucin; urea;
KCl; NaCl;
Na2HPO4;
CaCl2.4H2O
1/2160 2 h NaCl; pepsin; HCl 2 h NaHCO3
Oliver et al. 1999 [89] Wrist action
shaker
Filtration 0.45 μm 1/10 2 h, pH 1.3 to
3.0
Organic acids; HCl;
with(out) pepsin
16 h, pH 7.0 NaHCO3 with(out)
bile & pancreatin
Ellickson et al. 2001 [57] Bath set,
90 cyc/min
Centrifugation
(200 g; 20 min) &
(906 g; 15 min);
HNO3, 48 h;
filtration 0.45 μm
Mucin; urea; CaCl2.
H2O; NaCl; KCl;
Na2HPO4
1/2160 2 h, pH 1.4 Pepsin; NaCl; HCl 4 h, pH 6.5 NaHCO3
Oomen et al. 2002,
Van De Wiele et al. 2007
[82,87]; DIN test
Agitator,
200 rpm
Centrifugation
(7,000 g; 10 min)
1/50 2 h, pH 2.0 HCl; [pepsin; mucin]* 6 h, pH 7.5 Phosphate buffer;
[bile; trypsin;
pancreatin]*
Oomen et al. 2002,
Van De Wiele et al. 2007
[82,87]; SHIME test
Stirring,
150 rpm
Centrifugation
(7,000 g; 10 min)
1/2.5 to
1/40
3 h, pH 2.0
(fast) or 4.0 (fed)
Nutrilon plus; pectin;
mucin; cellobiose;
proteose peptone;
starch; glucose
5 h, pH 6.5 NaHCO3; pancreatin;
bile
Oomen et al. 2002,
Van De Wiele et al. 2007
[82,87]; TIM test
Peristaltic Ultrafiltration 5 min,
pH 5.0
Fast: 40 min, pH
4.5 to 1.8
HCl; lipase; pepsin*
0.5 mL/min
Fast: 5.3 h,
pH 6.5 to 7.2
NaHCO3;
pancreatin; bile*
1 mL/min
Fed: 4.5 h, pH
6.5 to 7.2
Fed: 1.5 h, pH
5.0 to 2.0
Yu et al. 2006 [113] Water bath,
90 rpm
Filtration 0.45 μm Mucin; urea;
KH2PO4; CaCl2.H2O;
NaCl, KCl
1/400 2 h, pH 1.4 NaCl; pepsin; HCl 2 h, pH 6.5 NaHCO3
Bruce et al. 2007 [94] Ar Centrifugation
(10,000 g; 15 min),
filtration 0.22 μm
1/100 1 h pH 1.3 (fast)
to 4 (fed)
Pepsin; HCl;
organic acids
3 h pH 7.0 NaHCO3; bile;
pancreatin
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Table 6 Examples of variants of physiologically based in vitro procedures (not calibrated) applied to Pb particles (2 pages) (Continued)
Saikat et al. 2007 [104] Centrifugation
(2,100 g; 25 min)
1/38-
1/100
1 h pH 1.1 or
2.5
Pepsin; organic
acids; HCl
4 h, pH 5.5 or
7.0
NaHCO3;
pancreatin; bile
Triantafyllidou et al. 2007
[26]
Gentle
mixing
No separation 1/16,667 3 h, pH 1.2 NaCl; pepsin; HCl
Turner and Ip 2007 [127] End-over-end Centrifugation
(2,100 g;10 min)
1/200 2 h, pH 2.5 Pepsin; HCl; Na malate &
citrate; lactic & acetic acids
4 h, pH 7.0 NaHCO3; bile;
pancreatin
Van De Wiele et al. 2007
[87]
Water rotator
set
Filtration 0.45 μm 1/100 1 h pH 2.5 Pepsin; HCl; Na citrate &
malate; lactate, acetate
4 h, pH 7.0 NaHCO3; bile;
pancreatin
Bosso and Enzweiler 2008;
Bosso et al. 2008 [107,114]
Slow orbital
+ Ar flux
Centrifugation
(5,000 rpm; 20 min)
1/100 1 h, pH 1.7 Pepsin; HCl; citric, malic,
acetic, & lactic acids
2 h, pH 7.0 NaHCO3; bile;
pancreatin
Turner et al. 2009 [128] Constant,
lateral
Centrifugation
(2,000 g; 10 min)
1/100-1/
143
1 h, pH 2.5 Pepsin; HCl; Na malate,
citrate; lactic & acetic acids
4 h, pH 7.0 NaHCO3; bile;
pancreatin
Sialelli et al. 2010 [115] Orbital,
150 rpm
1/100 1 h, pH 1.5 Pepsin; HCl; Na citrate; malic
& lactic acids
3.5 h, pH 7.0 Pancreatin, NaHCO3
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Table 7 Main bioaccessibility results for materials tested using an in vitro procedure calibrated with in vivo data
SUBSTRATE IVBA% REFERENCES
Flanders soil 91±4 [29,43,60,61,63,64,82,84,109]
RBALP (Gastric)
Oker 11 soil 56±4
47 Omaha community smelter soils, US 68-69 (average)
HER-2930 smelter soil, US 69±1.5 (using Dr Drexler’s Pb levels)
85±1.1 (using EPA’s average bulk Pb levels)
17 residential soils, tailings, and slags from mining waste sites, US 14±1.7 to 90±3.1
1 NIST paint 75±3.8
1 Galena 6±2.3
8 shooting range soils, US 83±1 to 100±3
20 soils from the N-S transect, US
(agricultural, grazing land, open range, forested land, residential, desert)
3.7 to 39
70 samples of tap water particles 1.5 to 100
9 soils from mining sites* 3.1±0.1 to 99.3±14.3 [86] RIVM (Intestinal)
1 NIST paint* + soil 86.2 ± 2.3
1 Galena* 1.7 ± 0.2
15 mining soils, France 9-75 (Intestinal) [65,66,95,133,134] UBM
10 smelting soils, France 34-90 (Intestinal)
27 urban topsoils, France 11-63 (Intestinal)
12 soils (mining, composite, phosphate-treated),
1 dust, from various studies (European and North American)
0.6±0.1 to 112.8±18.5 (Gastric)
0.1±0.1 to 89.5±91.3 (Intestinal)
2 urban residential soils, Australia 20.0±4.0 to 26.1±6.5 [67,68,112] SBRC (Intestinal)
3 domestic incinerator soils, Australia 11.7±2.8 to 22.5±5.0
3.2±2.6 to 8.5±0.6†
Brushal, Carl-1, Hamburg, and Oker-11 soils§ 30.7±6.1 to 62.9±11.0
9 shooting range soils, Australia 21.3-102.6
59±3.7 to 92±9.0 (3 soils)†
5 historical fill soils, Australia 5.5-26.1 (4 soils)
10.7±0.7 to 16.6±1.1 (2 soils)†
13 mining/smelting soils, Australia 11.6-82.5
31±18.4 to 74±17.3 (3 soils)†
1 gasworks, Australia 27.2
27±1.6†
1 geogenic, Australia 12.5
*Same test materials as in RBALP studies, 0.06 g; §soils tested by Marschner et al. [62]; †Smith, et al. [68].
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the highly heterogeneous nature of these substrates in
terms of Pb form, particle size, etc. The bioaccessibili-
ty of three slag materials was evaluated at 17, 20, and
73% [84]. Also, among mining site soils and urban top-
soils, the IVBA was shown to vary from low (9-14%) to
high (63-75%) [65].
Pb speciation
Speciation in the particles can be a strong indicator of
the potential bioavailability of Pb. Indeed, RBA estimates
can vary widely (6-105%) for Pb particles across thesame site or region (e.g. California Gulch, CO), reflecting
variability in their mineral composition and the potential
of Pb to be liberated [42]. According to Schoof et al., the
solubility of Pb minerals present in the test material
explains the observed differences in bioavailability
results [40]. In addition, Rasmussen et al. successfully
predicted their bioaccessibility results on dust from 924
Canadian homes by identifying the Pb phases present
with XANES, and further cumulating the bioaccessibility
specific to each phase [124]. Identifying the major spe-
cies present in a soil would therefore help in predicting
the extent of bioavailability. Schoof et al. classified the
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oxide [PbO]; average for Pb-manganese [Pb-Mn] oxides,
Pb-iron [Pb-Fe] oxides, and Pb carbonates; moderate for
Pb sulfates and Pb arsenate; and minimal for Pb phos-
phates [Pb-P] [40]. The reference USEPA classification
for bioavailability (and therefore bioaccessibility) after
several in vivo and in vitro studies varies from high for
cerussite [PbCO3] and Pb-Mn oxide (> 75%), to medium
for Pb-P and PbO (25-75%), to low for anglesite, galena,
Fe-Pb species and remaining Pb-based oxides (< 25%)
[43]. Drexler and Brattin observed the lowest bioaccessi-
bility for substrates containing anglesite or galena as
dominant Pb species (6-21%) [84]. On the contrary, sub-
strates with either PbCO3 or MnOOH as the dominant
Pb mineral systematically presented a high bioaccessibil-
ity (65-90%), in agreement with the data on juvenile
swine. Pb carbonate species are easily soluble, and this is
reflected in other in vitro results: Pb carbonates were
estimated to be 97% bioaccessible in the Schaider et al.
study [108]; hydrocerussite paint 69% bioaccessible prior
to cola addition in another study [93]; and Pb was 56%
(gastric) and 25% (intestinal) bioaccessible in the high
carbonate garden soil G1 in the Denys et al. study [96].
Soil remediation with phosphates has been shown to de-
crease Pb bioaccessibility, in agreement with the expected
low solubility of Pb-phosphate particles [114,118,120,135].
Nonetheless, a low bioavailability/bioaccessibility fraction
should not be interpreted as representing a low hazard po-
tential. Indeed, in the Schroder et al. study [70], the
bioavailability of Pb in the Pb-rich soil 9 (10,600 mg Pb/kg
soil) is medium to low (RBA 20%, ABA ~ 10%), but a dose
of 100 mg of soil ingested daily will release the same quan-
tity in the body, about 0.1 mg of Pb, like the highly Pb-
bioavailable but less Pb-rich soil 15 (RBA 74%, ABA ~
37%, 3230 mg Pb/kg soil) (authors’ calculation). Another
facet of speciation concerns the major impact of the rate
of pH change on the solution and mineralogical compos-
ition found at a given pH. Marked differences in solubility
were shown between tests conducted in dynamic versus
static pH adjustment conditions for a soil dominated by
cerussite and modified with hydroxyapatite [135]. The
differences reached up to three orders of magnitude in
the presence of phosphates, and were attributed to the
mechanisms that govern the amount of soluble Pb,
with adsorption/desorption phenomena decreasing the
amount of soluble Pb in dynamic systems.
Particle size
It is generally accepted that a small particle size provides
a high surface to volume ratio and an elevated poten-
tial for dissolution [69]. Indeed, Casteel et al. found a
high RBA (57-58%) for soils of ≤ 250 μm containing
a majority of particles ≤ 10 μm [49]. The significant
BLLs observed in piglets dosed with “predicted lowbioavailable” tailings were partly explained by the small
size of the galena crystals (mostly < 10 μm) that were
completely dissolved within 50–100 min at a low gastric
pH [79]. Rieuwerts et al. reported a bioaccessibility of
about 61-116% for particles < 64 μm, while particles
> 64 μm were 21 to 72% bioaccessible [117]. Mercier
et al. showed that Pb bioaccessibility generally decreased
with increasing granulometry (< 63 μm to 125–250 μm),
but remained stable or varied without any trend between
125–250 μm and < 2 mm, depending on the substrate
[119]. Yu et al. [113] did not find any significant differ-
ences in the bioaccessibility estimates between the dust
size fractions < 75 μm, 75–150 μm, and 150–250 μm,
and, finally, Morman et al. [109] found similar ranges for
soil particles < 2 mm (8.5-77%) as compared to particles
< 250 μm (3.7-45%), suggesting that small particles are
not always more bioaccessible. Such differences may be
partly explained by the Pb phase of the particles tested:
less soluble Pb phases (anglesite, pyromorphite, and ga-
lena) were more influenced by particle size than the
more soluble Pb phases in the Medlin study [88], bioac-
cessibility increasing about 4- to 13-fold between the
fractions < 38 μm and < 250–125 μm. Moreover, Ruby
et al. showed that Pb dissolution rates are not affected
by particle size, except for diameters less than 2.4 μm
[81]. Finally, Oliver et al. noted that greater bioaccessi-
bility for small particles is more evident for equivalent
diameters below 100 μm, so the impact of particle size
on bioaccessibility results would only be significant for
very small and colloidal particles [89].
For a given test material, an increase in bioaccessibil-
ity/bioavailability that is in inverse proportion to particle
size may reflect a relative enrichment in smaller size
fractions. Indeed, Juhasz et al. report up to five times
more Pb in the < 50 μm particle size fraction of sixteen
peri-urban soils [136]. Also noted were significant
increases in gastric-SBRC IVBA for six of those soils,
but no differences in intestinal-SBRC IVBA between the
size fractions. Madrid et al. observed a higher Pb content
in the clay fraction (< 2 μm) of urban soils from Sevilla,
as well as an increase in the bioaccessible Pb in this size
fraction [137]. Finally, a 110% average Pb enrichment
was measured in the particle size fraction adhering to
hands for different types of soils in Canada, as compared
to the bulk Pb content [138]. As the fraction adhering to
hands is usually smaller than the < 250 μm particle size
fraction traditionally used for soils, these authors recom-
mend conducting bioaccessibility experiments on small
particles, for example < 45 μm.
Matrix characteristics
The characteristics of the matrix surrounding Pb can
also influence Pb release for a given type of particle. Pb
bioaccessibility has been related to total Pb content in
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such as zinc, iron, and cadmium [133,139]. Strongly
positive linear relationships were found between Pb
bioaccessibility and Pb content in the soils [133]. It can
be expected that a higher Pb content will result in
greater bioaccessibility. However, Morman et al. found
no correlation between total elemental content (Pb, Cd,
Ni, Cr, and As) and the bioaccessible fraction for the
twenty soils from various sources [109]. Comparable
RBA results (56-58%) were obtained with Aspen Berm
and residential soils of comparable particle size, matrix,
and mineral type, although the Berm soil contained four
times as much Pb [49]. Oomen et al. also found higher
bioaccessibility for Flanders sandy loam (91%) than for
Oker 11 sandy loam (56%), although the latter contained
ten times more Pb [82]. This indicates that bioavailabil-
ity is more influenced by the particle type distribution
than by its Pb content.
Bioaccessible Pb was related to other characteristics of
the soil matrix than total metal content, such as carbo-
nates, clay, and organic matter, in soils from similar
sources [133,140]. However, another study did not find a
significant relationship between Pb bioaccessibility and
the total amount of carbonates in a variety of high Pb-
carbonate soils [96]. Caboche et al. found significant cor-
relation to the cation exchange capacity; organic matter;
and clay, manganese, phosphorus, and iron content for
soils from the same source. However, no correlations
were found when soils from all the sources tested were
pooled [134]. In addition, the bioaccessibility of twenty
soils from various sources in another study was not cor-
related to the organic carbon, pH, and clay percentage in
the soils [109]. These findings suggest that significant
relationships with soil characteristics can be found for
soils from the same source type, but that they cannot be
generalized to other matrices.
Overall, soil characteristics will impact Pb bioaccessi-
bility differently, depending on the Pb species present,
and cannot be used as a general predictor of bioaccessi-
bility, while Pb speciation may be more predictive of
bioaccessibility.
Gaps in bioaccessibility data
This review documented an abundance of peer-reviewed
studies on in vitro testing, on topics ranging from simple
leaching procedures to validated procedures calibrated
to in vivo animal studies, and their application to a range
of Pb bearing substrates. Among all the methods devel-
oped to estimate Pb bioaccessibility, only a few have
been successfully compared with in vivo data (Table 4),
and only the RBALP has been calibrated, validated, and
fully standardized [84]. Other procedures, such as UBM,
RIVM, and SBRC, have been highly correlated to in vivo
data, and sometimes nearly fully validated (UBM), andso their results can also be considered valid for improv-
ing exposure assessment and public health protection.
However, additional validation with statistical analysis
and round robin testing will be needed to standardize
these procedures.
A significant number of substrates were tested using
these validated procedures (Table 7). However, few data
(one) are available on bioaccessibility on dust, although
dust Pb content was evaluated at some of the sites stu-
died. Also, only one paint substrate was tested and the
NIST material used may not necessarily be representa-
tive of paint chips to which children are exposed. How-
ever, paint containing Pb is not unusual in toys and old
buildings [141], and recent results on paint chips using
HCl extraction show high variability of leachable Pb,
ranging from 4 to 100% [122]. As well, some HCl extrac-
tions performed on dust particles have shown that the
amount of leachable Pb is generally high [126], and this
is partly attributed to the small size of these particles. Pb
dust and Pb paint have been shown to be major contri-
butors to the BLLs of children [142]. Further research is
needed to quantify the variability in bioaccessibility for
these particles, to support the estimation of the contri-
bution of paint and dust particles to exposure, and to
help analyze the reported pica-caused BLL cases asso-
ciated with ingestion of these particles. There is also a
significant data gap regarding Pb particles from drinking
water systems. Early results using the RBALP adapted
for Pb particles from tap water show that the bioaccessi-
bility of particles generated from plumbing metals and
collected from distribution systems varies widely [29].
Such data are needed, considering that: (i) particulate Pb
can be sporadically high and is currently not fully con-
sidered in drinking water sampling and analysis meth-
ods; (ii) baby bottles may be prepared with tap water;
and (iii) tap water Pb particles and colloids are small and
may be highly soluble, depending on the forms present
[26,27,143].
Finally, most of the bioaccessibility results were mea-
sured in a fasting state, which is considered to be the
worst case ingestion scenario. This ingestion state may
be realistic for soil, paint, and dust particles, but not for
tap water Pb particles, which can be ingested in either
the fasting or the fed state. The oral bioavailability of Pb
in food cooked or prepared with high Pb particulate
water might also be a relevant route of exposure to study
[26]. However, the development and validation of a stan-
dardized in vitro test for a fed state would certainly be a
challenge, considering the variability of food that can be
ingested by children (other than milk) and the divergent
results observed for several types of food [88]. The most
disturbing finding is that higher bioaccessibility values
are found for in vitro tests performed with whole milk
powder than for those simulating a fasting state [62,87].
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increases the absorption of PbAc in rats [144]. This has
also been observed for hydrophobic organic compounds,
and can be explained by the formation of soluble metal
complexes with milk constituents [86,106]. Such infor-
mation may not have been considered in the past be-
cause the major sources of Pb exposure were air and
soil, and Pb exposure from these sources is not likely to
occur at the same time as milk ingestion. However, con-
sidering that water is now established as a significant re-
sidual source of Pb exposure and that baby bottles are
often prepared with tap water, the ingestion of formula
made in this way probably constitutes the worst case ex-
posure, as it involves both the dissolved and the particu-
late Pb in tap water. Therefore, it is not clear that
in vitro procedures in a fasting state will provide worst
case assessments of exposure for bottle-fed infants/chil-
dren. One in vivo study was performed with the simul-
taneous dosage of soil and milk powder on juvenile
swine [62]. However, the dosage of soil was not tested
on its own, precluding any comparison between Pb ab-
sorption from soil particles alone and Pb absorption
from particles in the presence of milk. The apparent in-
crease in Pb bioavailability when Pb is ingested with
milk certainly needs to be confirmed with an in vivo test
on piglets, to compare both soluble and particulate Pb
ingestion, with and without milk.
Conclusion
In vivo experiments on Pb particles have been carried out
using animal models on a wide range of particulate Pb
forms, mostly from contaminated soils. It is established
that there are substantial anatomical and physiological dif-
ferences between animal species and humans, especially
children. The scarcity of data providing a direct estimate
of the human absorption of Pb particles is a significant
limitation on our ability to estimate bioavailability, a short-
coming that is partially addressed by the use of the most
representative animal model. Of all the animal models
evaluated, juvenile swine are considered the most appro-
priate animal model for human exposure studies. How-
ever, results from animal models should always be
considered with caution when extrapolated to humans or
used to validate results from in vitro testing. Critical fac-
tors to consider in order to ensure relevance to public
health decision making include: (1) the limitations and
specific features of the animal model; (2) targeting the
human population in the design of animal studies, specif-
ically the appropriate developmental stage; and (3) the use
of plausible environmental doses and Pb speciation.
Results reporting Pb bioaccessibility reflect the experi-
mental conditions considered, and, in the absence of a
standard procedure, cannot be compared. At the same
time, this variability is inextricably linked to the naturalvariability of human exposure to Pb particulates. The
RBALP procedure seems well suited to Pb particles,
since its results for gastric extraction can be successfully
correlated to in vivo data on piglets. This test was com-
pletely validated and submitted to a rigorous QA/QC
protocol. The addition of an intestinal bioaccessibility
phase to better mimic Pb solubility at the neutral pH of
absorption (UBM, SBRC, RIVM) may refine the bioavail-
ability estimates. However, these tests are more costly
than the RBALP and quite tedious, and the full valid-
ation of the tests simulating an intestinal phase is likely
to be extremely challenging. The “stomach” UBM, which
is in the process to be fully validated, appears to be a re-
liable test, and offers the major advantage of estimating
the RBA of two other elements as well as Pb (arsenic
and cadmium).
Finally, the validated tests were applied on a significant
number of substrates, but mostly soils. The selection
does not cover the whole variety of possible matrices
surrounding Pb in environmental sources and other sig-
nificant sources of exposure, such as those of paint, as
well as dust and tap water. Testing these types of parti-
cles in vitro raises experimental challenges, because of
their heterogeneity and the small amounts of some of
them, but is needed to complete the input in exposure
models and risk assessment studies. The RBALP could
be adapted for estimating bioaccessibility from these
sources, since this test is quite simple to perform com-
pared to other procedures, and presents the highest de-
gree of standardization.Competing interests
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